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ABSTRACT 
 
 
Impact of Antidementia Medications on Neuropsychiatric Symptoms and  
 
Informal Costs of Caregiving in Dementia 
 
 
by 
 
 
Stephanie Behrens, Master of Science 
 
Utah State University, 2017 
 
 
Major Professor: JoAnn T. Tschanz, Ph.D. 
Department: Psychology 
 
 
To date, the most common pharmacological treatments for dementia are 
cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists (antidementia 
medications), which are associated with a delay in the progression of the cognitive and 
functional symptoms. Studies of the effects of antidementia medications on 
neuropsychological symptoms (NPS) show varying results. Presence of NPS can also 
affect the amount of time caregivers spend with persons with dementia, which can affect 
informal costs of the condition. This project used extant data from the longitudinal, 
population-based Cache County Study on Memory and Aging (CCSMA) and the 
Dementia Progression Study (DPS), which included permanent residents aged ≥ 65 of 
Cache County, Utah. Linear mixed models were used to assess the association between 
antidementia medications with informal costs and NPS. The first study examined whether 
antidementia medications were associated with a decrease in informal costs. Use of 
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antidementia medications was not significantly associated with informal costs (expβ = 
.79, p = .090). When restricting the sample to only the participants who were of mild 
dementia severity at baseline, antidementia medications were associated with a 28% 
decrease in informal costs (expβ = .72, p = .039). The second study evaluated whether 
antidementia medications were associated with a decrease in NPS. Results indicated that 
use of antidementia medications was associated with a 28% increase in NPS (expβ = 
1.28, p < .001). However, this association was no longer significant with the inclusion of 
covariates, in particular, the use of psychotropic medications. Use of any psychotropic 
medication was significantly associated with a 30% increase in Neuropsychiatric 
Inventory (NPI) score. Overall, the use of antidementia medications may not significantly 
reduce informal costs or NPS. The use of antidementia medications may reflect patterns 
of use that are prompted by severity of dementia and NPS.  
(130 pages) 
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PUBLIC ABSTRACT 
 
 
Impact of Antidementia Medications on Neuropsychiatric Symptoms and  
 
Informal Costs of Caregiving in Dementia 
 
 
by 
 
 
Stephanie Behrens 
 
 
Dementia-related diseases are progressive neurological disorders that can affect a 
person’s cognition and functional abilities, and also result in mental health symptoms 
commonly called neuropsychiatric symptoms (NPS). To date, the most common 
pharmacological treatments for dementia, “antidementia” medications, delay the 
progression of the cognitive and functional symptoms of the condition. Studies of the 
effects of antidementia medications on NPS show varying results. Presence of NPS can 
also affect the amount of time caregivers provide care with persons with dementia, which 
can affect informal costs of the condition. This project used extant data from the 
longitudinal, population-based Cache County Study on Memory and Aging (CCSMA; 
1994-2007) and the Dementia Progression Study (DPS; 2002-2013), which included 
permanent residents aged 65 years and above in 1995 in Cache County, Utah. Both of 
these studies were funded by grants through the National Institute on Aging, with 
participants and caregivers receiving $25 for each visit. Linear mixed models were used 
to assess the association between antidementia medications with informal costs and NPS. 
The first study examined whether use of antidementia medications was associated with a 
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decrease in informal costs. The median daily informal cost of care by dementia severity 
was as follows: cost for mild dementia was $9.92, cost for moderate dementia was 
$30.02, and cost for severe dementia was $46.99. Antidementia medication use was not 
associated with informal costs (expβ = .79, p = .090); however, when restricting the 
sample to only the participants who were of mild dementia severity at baseline, 
antidementia medications were associated with a 28% decrease in informal costs (p = 
.039). 
The second study evaluated if antidementia medications was associated with a 
decrease in NPS. Use of antidementia medications was associated with a 28% increase in 
NPS (expβ = 1.28, p < .001). However, this association was no longer significant with the 
inclusion of covariates, in particular, the use of psychotropic medications. Use of 
psychotropic medications was significantly associated with a 30% increase in NPS. 
Compared to mild dementia severity, moderate CDR was significantly associated with a 
49% increase in NPS and severe CDR was significantly associated with a 60% increase 
in NPS. Overall, the use of antidementia medications may not significantly reduce 
informal costs or NPS. These studies suggest that persons who use antidementia (and 
psychotropic medications) are more likely to be experiencing more severe symptoms of 
dementia. Future work exploring patterns in the initiation and duration of use may be 
helpful to further examine the potential beneficial effects of these treatments.  
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 CHAPTER 1 
 
INTRODUCTION 
 
 
 Dementia-related diseases affect approximately 46.8 million individuals 
Alzheimer’s Disease International [ADI], 2015). These numbers are projected to double 
every 20 years, resulting in estimates of 131.5 million individuals with the disease in 
2050 (ADI, 2009, 2015). With the current prevalence of dementia, the 2015 worldwide 
total cost of the disease was estimated at U.S. $818 billion and is projected to increase to 
two trillion dollars by 2030 (ADI, 2013). The costs of care for dementia related diseases 
can be broken down into formal and informal costs, with informal costs being the focus 
of the present study.  
Formal costs of dementia are defined as the act of paying for services, such as 
healthcare, full-time professional care, and medications. Informal costs are administered 
aid where no money is exchanged but where there is a loss of income or leisure time of 
the person administering care (Gillespie et al., 2013; Hurd, Martorell, Delavande, Mullen, 
& Langa, 2013; Langa et al., 2001). Family members typically incur informal costs as 
unpaid caregivers. The informal costs of care for persons with dementia living in the 
community are estimated to account for approximately 70%-80% of the total costs of the 
disease (Rapp et al., 2012; Schwarzkopf et al., 2011). The high use of informal care 
emphasizes how the economic impact of dementia would increase astronomically if 
unpaid caregivers did not provide the majority of care.  
 Extensive research is taking place to develop treatments for dementia in order to 
decrease the economic and emotional costs associated with the condition. The most 
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common pharmacological treatments to date are “antidementia” medications, 
cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, which 
delay the progression of the cognitive and functional symptoms of the condition. 
According to Hartz, Getsios, Tao, Blume, and Maclaine (2012), a study in Germany 
found antidementia medications, donepezil and memantine, to be cost effective for the 
total cost of Alzheimer’s disease when compared to no treatment. The cost effectiveness 
concerned improving the cognitive and functional status of the individual, decreasing the 
severity of the disease, and delaying institutionalization. Although the benefits of taking 
antidementia medications have been well documented, a majority of the studies have 
relied on clinic-based samples followed for a limited time period (i.e., a few months) 
(Burns et al., 2009; Burns, Spiegel, & Quarg, 2004; Hashimoto, Yatabe, Kaneda, Honda, 
& Ikeda, 2009; Rive et al., 2012). Since dementia is progressive, the short period of study 
poses a problem when generalizing results to individuals at various stages and lengths of 
illness. Results of clinical trials may also be limited in generalizability due to strict 
eligibility criteria.  
While the beneficial effects of antidementia medications on cognitive and 
functional impairments appear to be a common finding across studies, studies of 
antidementia medications and neuropsychiatric symptoms (NPS) show varying results. 
Some studies show no effects of antidementia medications on reducing NPS (Hellweg, 
Wirth, Janetzky, & Hartmann, 2012), while other studies show antidementia medications 
to have moderate effects in reducing NPS (Grimmer & Kurz, 2006). NPS are significant 
features of dementia, in their nearly universal occurrence (Cummings, Mackell, & 
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Kaufer, 2008; Tschanz et al., 2011), their major effects on caregiver burden (Allegri et 
al., 2006; Rymer et al., 2002), and the informal costs of care (Rattinger et al., 2015). 
Based on the current literature, it is unclear whether antidementia medications effectively 
reduce the occurrence or severity of NPS, and whether this in turn decreases informal 
care needs and informal costs of the condition.  
The purpose of this project was to evaluate how antidementia medications affect 
the occurrence and severity of NPS and the costs of informal dementia care. The present 
study examined a community-, population-based sample of persons with dementia 
followed for up to 10 years, with most individuals being followed from a few years of 
dementia onset up to their deaths. In Study 1 of the project, I examined whether treatment 
with antidementia medications was associated with lower informal care costs in dementia 
related-diseases and in Study 2, I examined whether treatment with antidementia 
medications was associated with less severe NPS in persons with dementia. 
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CHAPTER 2 
 
STUDY 1: INFORMAL COSTS AND ANTIDEMENITA MEDICATIONS 
 
 
Abstract 
 
 
Antidementia medications (cholinesterase inhibitors and N-methyl-D-
aspartate receptor antagonists) are associated with a delay in the progression of dementia 
symptoms. The severity of dementia symptoms (cognitive, functional, 
neuropsychological) can affect the informal cost of the condition. This project included 
277 participants with dementia from the longitudinal, population-based Dementia 
Progression Study (DPS), which is the ancillary study to the Cache County Study on 
Memory and Aging (CCSMA). Medication use was based on inspection of each 
participant’s medications and interview, and caregiving hours were estimated using the 
Caregiver Activity Survey. Informal costs were calculated using the replacement cost 
method by multiplying hours of care by Utahan median wages in the visit year, then 
adjusted for inflation and expressed in 2015 dollars. Linear mixed models, using the 
gamma log-link function, assessed the association between antidementia medications 
with informal costs. The median daily informal cost of dementia care by severity of 
dementia was as follows: mild dementia was $9.92, moderate dementia was $30.02, and 
severe dementia was $46.99. Use of antidementia medications was not significantly 
associated with informal costs (expβ = .79, p = .090). When restricting the sample to only 
the participants who were of mild dementia severity at baseline, antidementia 
medications were associated with a 28% decrease in informal costs (expβ = .72, p = 
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.039). The use of antidementia medications significantly reduces informal costs when 
started at earlier dementia severity stages. 
 
Introduction 
 
 
 With the prevalence of dementia-related diseases increasing exponentially, the 
global costs associated with the condition are also increasing. In the U.S., the costs of 
Alzheimer’s dementia, not adjusting for coexisting health conditions, was estimated at 
$203 billion in 2013. These costs can be broken down into costs to public and private 
sectors of the economy including $113 billion from Medicare, $41 billion from Medicaid, 
$44 billion from out-of-pocket costs, and $29 billion from other payment sources (“2015 
Alzheimer’s facts and figures,” 2015). If current trends continue, the costs of dementia 
are projected to increase approximately 80% to one trillion in U.S. dollars (2015) by 2050 
(ADI, 2013; “2015 Alzheimer’s facts and figures,” 2015; Hurd et al., 2013).  
 The cost estimates for dementia include the costs of a wide range of services 
provided for the individuals and their families, and can be broken down into the 
categories of formal or informal costs. The formal costs of dementia are derived from 
formal care and can be broken down into broad categories of medical care, full-time 
professional care, and medications. From a societal perspective the total cost for dementia 
per U.S. citizen was estimated at approximately $41,689 in 2014 dollars (“2014 
Alzheimer’s Facts and Figures,” 2014). Formal costs of dementia in the U.S. include 
public payers such as Medicare, Medicaid, and other public entities provided by state or 
local governments. According to the “2014 Alzheimer’s Facts and Figures” 2014), the 
6 
 
average Medicare costs for persons with dementia was three times higher than their 
similar aged peers without dementia, and the average Medicaid costs, including nursing 
home care, for persons with dementia in 2014 was 19 times higher (“2014 Alzheimer’s 
Facts and Figures,” 2014; “2015 Alzheimer’s facts and figures,” 2015). If current trends 
continue, it is estimated that by 2050, Medicare and Medicaid costs could increase by 
500% (“2014 Alzheimer’s Facts and Figures,” 2014). Within Medicare and Medicaid 
spending, the largest component generally has been attributed to institutionalized care, 
which is estimated to exceed Medicare and Medicaid costs by 2 to 3 times those of 
persons living in the community (Leon, Cheng, & Neumann, 1998). Estimates show that 
Medicare and Medicaid pay approximately 70% of the costs of institutional care of 
dementia (Lin et al., 2013), with Medicare and Medicaid paying the average annual cost 
of U.S. $33,544 2015 per person (“2016 Alzheimer’s facts and figures,” 2016). Studies 
on the economic impact of dementia have been studied to a greater degree in European 
countries. While such studies can offer insights on sources of costs, estimates may not be 
generalizable to the U.S. due to differences in culture, economics, and health care 
systems. Thus for U.S. data, the majority of cost estimates are based on data from large 
insurance databases such as Medicare; however, as where dementia is identified through 
claims data, such an approach tends to overlook milder cases of dementia (Taylor, 
Ostbye, Langa, Weir, & Plassman, 2009).  
 
Informal Costs 
Informal care is aid administered by family members or others who are not 
reimbursed for their services. Informal family caregivers provide about 83% of home 
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care for people with dementia (“2016 Alzheimer’s facts and figures,” 2016). In the U.S. 
in 2015, 18.1 billon hours of informal care was provided to persons with dementia, which 
was valued at $221.3 billion 2015 U.S. dollars (“2016 Alzheimer’s facts and figures,” 
2016).  
 Several approaches have been used to calculate informal costs of dementia care, 
including forgone wages/lost earnings, opportunity costs, and replacement wages. 
Forgone wages/lost earnings are calculated by using the wages the caregiver would have 
received if employed, opportunity costs are measured by the value of lost income as well 
as lost leisure time of the caregivers, and replacement wages are measured by the wage a 
paid professional would have been given to provide care if the caregiver was unable to 
(Fillit & Hill, 2004; Gillespie et al., 2013; Hurd et al., 2013; Langa et al., 2001; Leicht et 
al., 2011; Moore, Zhu, & Clipp, 2001; Murman & Colenda, 2005). Forgone wages and 
lost earnings are appropriate for calculating informal costs when the caregiver is 
employed, while opportunity costs may be more appropriate for calculating informal 
costs of a retired caregiver. In a review of the economic impact of AD, it was suggested 
that the lost earnings method might underestimate the economic impact of informal care 
because this method does not calculate informal cost estimates for caregivers who are not 
in the work force (e.g., retired spouse; Murman & Colenda, 2005). Fillit and Hill 
suggested that different approaches may be better for estimating costs based on the 
caregivers’ situation. The opportunity cost approach puts value on the caregiver’s time 
and is considered the best approach for caregivers who are employed and likely 
sacrificing hours at work to be a caregiver (Fillit & Hill, 2004). Replacement wages 
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assume that if there was not an informal caregiver providing services, the individual with 
dementia would need formal services, for example, nursing or home health services. For 
unemployed caregivers, the review found that the replacement wages approach was 
commonly used to estimate informal costs (Fillit & Hill, 2004), and this approach was 
used recently in the Cache County Dementia Progression Study in a sample consisting of 
both employed and unemployed/retired caregivers (Rattinger et al., 2015).  
 
Estimates of Informal Costs 
 
There is a limited body of literature on the informal costs of dementia care in the 
U.S. One of the first published U.S. studies used the Asset and Health Dynamics 
(AHEAD) data, which is comprised of community dwelling individuals. They employed 
the 1998 national average wage for a home heath aid (mean wage of $8.20 per hour) and 
found a yearly cost of $3,630 for mild dementia, which rose to $17,700 for severe 
dementia (Langa et al., 2001). In further exploring variations in costs, the authors used a 
range of wages from the 10th percentile of the national home health aids wage of $5.90 to 
the 90th percentile wage of $10.80 (Langa et al., 2001). At the low end, mild dementia 
cost $2,610 per year and severe dementia cost $12,730 per year, while at the upper end, 
mild dementia cost $4,780 per year and severe dementia cost $23,310 per year in 2001 
dollars (Langa et al., 2001). While a strength of this study was a national population-
based sample, no information was available on potential modifiers of informal costs, such 
as neuropsychiatric symptoms (NPS) and comorbidities. Additionally, costs were based 
on cross-sectional analysis in that longitudinal data were not available.  
 Another U.S. cost study enrolled male veterans living in the community (Moore et 
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al., 2001). Using the replacement wage approach, the authors applied the market price for 
various types of formal care services including physical care, personal management, and 
housekeeping (Moore et al., 2001). Estimated weekly informal costs, in 1998 dollars 
ranged from $45 when the care recipient had no impairment in activities of daily living 
(ADL) to $270 when the care recipient was not able to perform any ADLs (Moore et al., 
2001). The study also calculated the caregivers’ lost earnings with the average annual 
loss of $10,709, which between $10,000 to $12,000 per year as dementia progressed 
(Moore et al., 2001). Study limitations included the cross-sectional nature and the 
restricted nature of the sample.  
  More recently, Hurd et al. (2013) compared informal cost estimates of forgone 
wages and replacement wages in a nationally representative U.S. sample from the Health 
and Retirement Study (HRS). The advantage of using forgone wages lay in the 
assumption that caregivers were presumably giving up time at their jobs to assist the 
individual with dementia. The forgone wage for employed caregivers was estimated by 
the caregiver’s self-reported wages and for caregivers who were not employed, their 
forgone wages were calculated by averaging wages for persons with similar demographic 
characteristics (age, sex, and education level; Hurd et al., 2013). Replacement costs of 
informal care were calculated by using the market cost of the equivalent services 
purchased through a home health agency. After controlling for comorbidities, costs based 
on annual forgone wages were estimated at $41,689 (with 95% CI, $31,017 to $52,362) 
and costs based on replacement wages were estimated at $56,290 (with 95% CI, $42,746 
to $69,834) based on the 2010-dollar value (Hurd et al., 2013). Estimates of unpaid 
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caregiving revealed forgone wages accounted for 31% of the total cost while replacement 
wages accounted for 49% of the total cost (Hurd et al., 2013). In addition to using two 
methods to calculate informal costs, the other strengths of the study included the large 
representative sample. However, indicators of dementia severity were not available. 
Apart from the AHEAD and the veterans study, few U.S. studies have examined 
modifiers of the informal costs of dementia care. More information is available from 
international studies. The German Initiative Demenzversorgung in der Allgemeinmedizin 
(IDA) project evaluated overall costs of 383 individuals with mild and moderate 
dementia living in the community (Schwarzkopf et al., 2011). The average annual cost 
for individuals with mild dementia in 2008 was €30,803 and for individuals with 
moderate dementia was €52,335, controlling for age and gender (Schwarzkopf et al., 
2011). In this sample, informal care was 4-fold the cost of formal care and accounted for 
approximately 80% of total costs (Schwarzkopf et al., 2011).  
Dementia severity measured by cognitive and functional impairments was 
examined in a 2-year longitudinal study of 1,131 community dwelling French individuals 
with AD (Rapp et al., 2012). In this study, informal costs were estimated by caregiver 
time spent on surveillance, ADL, and instrumental activities of daily living (IADL). 
Formal medical costs were measured by any hospital or clinic visit, and medication costs 
and the formal non-medical costs were measured by day care, alarm services, and home 
help (Rapp et al., 2012). Cognitive decline significantly impacted informal costs more 
than medical and non-medical costs, and functional decline impacted formal non-medical 
costs more than formal medical and informal costs. All analyses controlled for care-
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recipient age at baseline, gender, education, time since AD diagnosis, and caregiver 
gender (Rapp et al., 2012). These results suggest that mild stages of dementia tend to cost 
more for informal care, but with the onset of ADL impairment, the cost burden switches 
to formal costs. This study also found mild AD was the source of the most expensive 
informal costs (Rapp et al., 2012). By contrast, a 2-year German longitudinal study of 
175 persons with dementia found IADL impairment to be a stronger predicator of 
informal costs than cognitive impairment (Leicht et al., 2013). However, since IADL 
impairments are usually present at earlier stages of AD and personal ADL impairments in 
mid-to-late stages, these results also support the observation that impairment in functional 
abilities also drive informal costs early in the disease course.  
NPS may also affect the costs of dementia care. A Swedish study consisting of 92 
dyads of persons with dementia and their caregivers, evaluated how time was spent in 
informal caregiving [e.g. assisting with ADLs, IADLs, and supervision or surveillance 
(Wimo, Von Strauss, Nordberg, Sassi, & Johansson, 2002)]. Results found that 
supervision or surveillance constituted a large part of informal care, particularly in cases 
of moderate dementia severity and also in cases with high amounts of NPS (Wimo et al., 
2002). Beeri, Werner, Davidson, and Noy (2002) showed approximately 30% of total 
costs and 65% of informal costs were attributable to managing NPS in community 
dwelling individuals with AD in Israel. A Canadian study of 500 individuals and their 
caregivers found that even with mild dementia, the presence of NPS increased the cost of 
care dementia care, and in particular, informal costs (Herrmann et al., 2006). While this 
study found that NPS contribute to higher costs, the authors did not calculate what these 
12 
 
costs were and if they were statistically significant compared to the absence of NPS 
(Herrmann et al., 2006).  
A U.S. study examined a representative sample (The Aging, Demographics, and 
Memory Study-ADAMS) of the HRS (Okura & Langa, 2011). When compared to 
individuals without NPS, individuals with one to two NPS had an increase of 10 hours of 
informal care per week with an additional 12.4 hours of supervision; individuals with 
three or more NPS had an increase of 18.2 hours of informal care with an additional 28.7 
hours of supervision (Okura & Langa, 2011). The NPS associated with the highest 
informal care hours were agitation, anxiety or irritation, depression, disinhibition, and 
aberrant motor behaviors (Okura & Langa, 2011). The positive association between NPS 
and hours of informal care remained even after adjusting for cognitive deficits and 
medical comorbidities, but not medication use (Okura & Langa, 2011). Limitations to the 
preceding studies is their cross-sectional nature, or with respect to the international 
studies, the short study period (e.g., 6 months to 1 year).  
Two U.S. longitudinal studies examined the effects of NPS and the informal costs 
of dementia care. The U.S. Predictors Study enrolled 204 persons with AD from three 
university-based research clinics and followed them longitudinally from 1990 to 2004 
(Zhu et al., 2006a). This study found that cognitive and functional abilities were 
associated with informal costs, but no association between NPS and informal costs. The 
authors attributed this to the crude measurements of the NPS, which was dichotomously 
measured by the presence or absence of psychiatric symptoms, depressive symptoms, and 
behavioral problems (Zhu et al., 2006a). While one of this study’s strength was the long 
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follow-up time, the participants represented a unique sample of AD patients treated at 
university dementia clinics, and thus results may not generalize to other populations. In a 
population-based sample from the Cache County Dementia Progression Study, Rattinger 
and colleagues found that when controlling for cognitive impairment, more severe NPS 
was associated increased informal care costs. This finding raises the possibility that the 
treatment of NPS may reduce informal costs (Rattinger et al., 2015).  
With the informal costs of dementia care increasing with severity of dementia and 
possibly NPS, it is unclear if dementia treatments reduce costs. In 1993, the U.S. Food 
and Drug Administration (FDA) approved the first antidementia medication, tacrine, a 
cholinesterase inhibitor (ChEI). Due to adverse side effects, it is no longer on the market 
(Atri, 2011). Several antidementia medications have since received FDA-approval 
including the cholinesterase inhibitors (ChEIs) donepezil (Aricept), galantamine 
(Razadyne), rivastigmine (Exelon), and an N-methyl-D-aspartate (NMDA) receptor 
antagonist, memantine (Namenda; Atri, 2011). To date, there has not been substantial 
evidence to show superior efficacy of one ChEI over another, but studies have shown 
combination treatment (ChEI + memantine) is advantageous over monotherapy (ChEI 
alone; Atri, 2011).  
Rountree, Atri, Lopez, and Doody (2013) reported that in short-term randomized 
controlled trials (RCTs) ranging from six months to one year, antidementia medications 
improved or decreased the rate of cognitive decline in AD and that long-term 
observational controlled (LTOC) studies found that persistence of medication use 
reduced cognitive, functional, and global decline (Rountree et al., 2013). The results from 
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these studies also showed that combination therapy including memantine was superior to 
ChEI monotherapy (Rountree et al., 2013).  
The use of antidementia medications may also reduce NPS (Grimmer & Kurz, 2006; 
Rodda, Morgan, & Walker, 2009), which together with their cognitive and functional 
effects may in turn affect time spent caregiving and caregiving burden, which may 
potentially reduce indirect costs.  
The purpose of this study was to examine whether the use of antidementia 
medications is associated with lower informal care costs in the population-based study, 
the Cache County Dementia Progression Study. This study’s sample has several 
advantages including the enrollment of community dwelling individuals and high 
participation rates with follow-up up to 10 years. Particularly, the longitudinal nature of 
this study allows for disease severity to be included as a factor when estimating informal 
cost. 
 
Methods 
 
Sample 
 This project used extant data from the Dementia Progression Study (DPS; 2002 – 
2013), which enrolled and followed persons with dementia identified from the 
longitudinal, population-based Cache County Study on Memory and Aging (CCSMA). 
The CCSMA included permanent residents of the county aged ≥ 65 years in 1995, and 
examined the prevalence, incidence, and risk factors of dementia in this U.S. county. In 
Wave 1, CCSMA enrolled 5,092 (89.7%) of the eligible individuals in the county 
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(Breitner et al., 1999) and subsequently conducted three additional triennial waves of 
dementia screening and evaluation described briefly below.  
In the first stage of CCSMA screening, participants were given the 100-point 
Modified Mini-Mental State Examination (3MS) cognitive screener or if unable, a proxy 
informant completed the Informant Questionnaire for Cognitive Decline (IQCODE; 
(Jorm, Scott, & Jacomb, 1989)). If an individual’s 3MS score was below 87, if the 
IQCODE was > 4.23, or if he/she was a member of a designated subsample to complete 
all evaluation stages, a knowledgeable informant completed a dementia questionnaire 
(DQ) with a technician. The DQ is a 50-item semistructured interview on dementia 
symptoms and general medical history, the results of which were then rated for degree of 
cognitive impairment by a neuropsychologist and geriatric psychiatrist. Individuals with 
ratings of questionable or probable dementia were asked to undergo a clinical assessment, 
which was conducted by a research nurse and psychometrist. In the clinical assessment, 
the research nurse evaluated the participant’s medical history and current medications 
with an informant and completed blood pressure measurement and a standardized 
neurological examination with the participant. The psychometrist administered a battery 
of neuropsychological tests (Tschanz et al., 2000) to the participant. Additionally, a 
knowledgeable informant completed the Neuropsychiatric Inventory (NPI). 
 As described previously (Breitner et al, 1999), a neuropsychologist, geriatric 
psychiatrist, and examining nurse and psychometrist reviewed the clinical assessment 
results. A preliminary diagnosis of dementia was given if symptoms met the criteria from 
the Diagnostic and Statistical Manual-III-R (DSM-III-R; American Psychological 
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Association [APA], 1987). Individuals, who received a classification of dementia or 
“mild/ambiguous” (a state designating prodromal AD), were sent for follow-up 
laboratory testing and neuroimaging (complete blood counts, routine chemistries, serum 
B-12, folate, thyroid function test, urinalysis, and Magnetic Resonance Imagining (MRI) 
or Computed Tomography (CT) scan. Persons with suspected dementia were examined in 
their residence by a geriatric psychiatrist or neurologist who repeated the neurologic 
examination, Mini-Mental State Exam (MMSE), and clinical history. After a review of 
all available clinical exams, a panel of expert clinicians consisting of geriatric 
psychiatrists, a neurologist, neuropsychologists, and a cognitive neuroscientist assigned a 
final diagnosis. A diagnosis of AD was assigned according to criteria of the National 
Institute of Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease 
and Related Disorders Association (NINCDS-ADRDA). A Vascular Dementia (VaD) 
diagnosis was given based on the National Institute of Neurological Disorders and 
Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences 
(NINDS-AIREN) criteria. Diagnoses of other dementias followed standard research 
criteria. Additionally, age of dementia onset (age at which the individual met DSM-III-R 
criteria for dementia), severity of dementia using the Clinical Dementia Rating (CDR; 
Hughes, Berg, Danzinger, Coben, and Martin (1982), and rating of overall health with the 
General Medical Health Rating (GMHR; Lyketsos et al., 2005) were assigned. Persons 
with dementia completed a clinical assessment 18 months later to clarify the diagnosis 
(Breitner et al., 1999).   
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Procedures 
From 2002 to 2007, the individuals who were identified with incident dementia 
(newly onset at each wave) in the CCSMA and their caregivers were invited to participate 
in the DPS (Tschanz et al., 2011). The DPS was a longitudinal study running from 2002 
to 2013 and examined factors that affected the rate of dementia progression in persons 
with dementia. A research nurse and psychometrician conducted in-home evaluations of 
the participants and their caregivers approximately every 6 to 8 months. The in-home 
evaluations consisted of a 45- to 60-minute neuropsychological test battery, brief 
neurological and physical examination, assessment of functional abilities using the CDR 
and Dementia Severity Rating Scale (DSRS; Clark & Ewbank, 1996), interview of health 
and psychiatric conditions, medication review and assessment of the caregiver’s well-
being and time spent providing care (Tschanz et al., 2011).  
Outcome variable. The Caregiver Activity Survey (CAS; Appendix E) was used 
as a basis to estimate informal costs of dementia care across all caregivers (Davis et al., 
1997). The CAS was administered to the caregiver annually at alternating (odd 
numbered) visits in the DPS. The CAS has a total of six items, which assess how much 
assistance over the last 24 hours all caregivers provided the individual with dementia 
(Davis et al., 1997). These tasks included communicating with the person, using 
transportation, eating, dressing, supervising, and looking after one’s appearance (Davis et 
al., 1997). The items were summed together to yield a total. This project imposed a 
maximum of 16 hours per day, allowing for eight hours of sleep as done in previous 
research (Penrod, Kane, Finch, & Kane, 1998; Zhu et al., 2006b). The CAS has high test–
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retest reliability, with ICC = .88 as reported previously (Davis et al., 1997). The CAS 
also has strong convergent validity with measures of cognitive ability including the 
Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog), r = .61 and the MMSE, 
r = -0.57 (Davis et al., 1997). This is similar to the longitudinal findings of the CAS with 
significant correlations with the MMSE, r = -.58 and the ADAS cognitive subscale, r = 
.56 (Marin et al., 2000).  
An estimate of informal costs was calculated using the hours reported on the CAS 
using the replacement wages method. Replacement wages (Hurd et al., 2013) were 
calculated by assigning values to the services from the cost equivalent of the median 
wage of Utahans in the year of the visit, consistent with the approach used in this sample 
by Rattinger et al. (2015). DPS did not obtain data on each caregiver’s salary so that 
estimates for forgone wages or opportunity costs could not be calculated. Also consistent 
with Rattinger et al., the Medical Consumer Price Index (MCPI) multiplier, which is 
based on the annual average of “medical care services” from the Urban Consumer Price 
Index (CPI-U), was used to account for changes in market price over the years of data 
collection of the study (2002-2012; U.S. Department of Labor, Bureau of Labor 
Statistics, 2016). For example, of the conversion of 2002 Utah median hourly wage into 
2015 dollars 2002 MCPI was calculated by dividing the 2015 CPI-U annual average of 
476.171 by the 2002 CPI-U annual average of 292.9 (476.171/292.9 = 1.626). The 
resulting value (1.626) was multiplied by the 2002 median Utah hourly wage of $12.23 
totaling $19.88. Table 2.1 outlines the values that were obtained through the U.S. Bureau 
of Labor’s Statistics including medium wage and the CPI-U (U.S. Department of Labor, 
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Table 2.1 
Median Wage in Utah Per Year and Consumer Price Index 
Year Median Wage Urban consumer 
price index  
2002 12.23 1.63 
2003 12.45 1.56 
2004 12.69 1.48 
2005 12.94 1.41 
2006 13.46 1.36 
2007 13.99 1.29 
2008 14.48 1.24 
2009 14.79 1.20 
2010 15.04 1.16 
2011 15.41 1.12 
2012 15.75 1.08 
 
 
2016; U.S. Department of Labor, Bureau of Labor Statistics, 2016).  
Predictor variables. At each visit, medication use was recorded by the research 
nurse who inspected the medicine chest for each participant following methods described 
previously (Medication Record; Appendix A; Zandi, 2005). Because information on 
medication use between visits was not available, medications used at consecutive visits 
were assumed to be taken continuously between visits. Medications were reviewed and 
coded using the Mosby Drug Reference System (Skidmore-Roth, 2009).  
Medications of interest included antidementia medications, psychotropic 
medications, and medications with anticholinergic properties. The latter two categories 
were included as covariates in statistical analyses due to their effects on NPS or 
cognition, and therefore potentially affecting informal costs. Subjects were classified 
according to use of antidementia medication (CHEIs or NMDA receptor antagonists) as 
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currently using vs. not currently using. Antidementia medications were used in the 
analysis to evaluate the effects on informal costs. The psychotropic medication classes 
included antidepressants, antipsychotics, mood stabilizers and sedatives, hypnotics, and 
anxiolytics. The antidepressant drugs included selective serotonin reuptake inhibitors 
(e.g. citalopram), selective norepinephrine reuptake inhibitors (e.g. mirtazapine), 
monoamine oxidase inhibitors (e.g. phenelzine), tricyclics (e.g. amitriptyline), and other 
antidepressants (e.g. maprotiline). Antipsychotic medications consisted of first generation 
(e.g. haloperidol) and second generation (e.g. quetiapine). The sedatives, hypnotics, and 
anxiolytics included were barbiturates (e.g. pentobarbital) and benzodiazepines (e.g. 
flurazepam), and the mood stabilizers included were lithium, carbamazepine, lamotrigine, 
and valproic acid.  
Psychotropic medications were included as a covariate because their use may 
diminish NPS, and therefore potentially be associated with informal costs. These 
psychotropic drug classes were condensed into a current vs. not current use. Medications 
with anticholinergic properties were classified using The Anticholinergic Cognitive 
Burden Scale (ACBS, 2012; see Appendix B. The ACBS is a list of anticholinergic 
medications ranked from 1 to 3, with level 1 meaning possible anticholinergic effects and 
levels 2 and 3 indicating definite anticholinergic effects (Campbell et al., 2010). 
Medications classified as having level two or three anticholinergic effects were used as a 
covariate as either current or not current use at each visit. Anticholinergic medications 
were included as a covariate because of potential adverse effects on cognition, which also 
may be associated with informal costs (Carriere et al., 2009). 
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 Additional covariates included the CDR (Appendix C), which is a rating scale 
completed by the nurse and based on a semi-structured interview administered every visit 
to the caregiver and participant to estimate the severity of cognitive and functional 
impairments across six domains: memory, orientation, judgment and problem solving, 
community affairs, home and hobbies, and personal care (Hughes et al., 1982). The CDR 
global scoring method involves a scale ranging from 0 = no impairment, 0.5 = 
questionable impairment, 1 = mild impairment 2 = moderate impairment, 3 = severe 
impairment, 4 = profound impairment, and 5 = terminal, while the CDR Sum of Boxes 
(CDR-SB) is calculated by adding all of the domain scores together to create a total score 
ranging from 0 = no impairment to 18 = severe impairment (Hughes et al., 1982; 
O'Bryant et al., 2010). Due to limited number of participants rated in the extremes (e.g., 
very mild or severe), the data were collapsed into the following ranges 0, .5, 1 = mild 
impairment, 2 = moderate impairment, 3, 4, 5 = severe impairment. The overall inter-
rater reliability of the CDR has been reported as moderate to high with a kappa = 0.62 
(Rockwood, Strang, MacKnight, Downer, & Morris, 2000). 
Overall health status was also used as a covariate, and assessed using the General 
Medical Health Rating (GMHR, see Appendix D), which provides a global rating of an 
individual’s health. The rating is based on information obtained at each visit from the 
medical interviews conducted by the research nurse, a review of medications and brief 
physical and neurological exams (Lyketsos et al., 2005). In assigning the ratings, 
consideration is given to the number of conditions, acute or chronic status, and whether 
the conditions are controlled by treatments (Lyketsos et al., 2005). Based on this 
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information, a geriatric psychiatrist and clinical assessment team assigned the individual 
a ranking from one to four: “excellent” (4), “good” (3), “fair” (2), or “poor” (1) (Lyketsos 
et al., 2005). Due to limited numbers of participants falling in the poor and fair ranges, 
data were collapsed into the following groups: “poor or fair,” “good,” and “excellent.” 
The inter-rater reliability of the GMHR has been examined in a random sample of 150 
participants of the Cache County Study and showed good inter-rater reliability, r = .704, 
p < .001 (Lyketsos et al., 2005). In a separate sample, the GMHR demonstrated 
concurrent validity with number of medical diagnoses and medications as well as 
predictive validity in its association with mortality (Lyketsos et al., 1999). The interrater 
reliability of the GMHR was also high in this study with a weighted kappa of .93 
(Lyketsos et al., 1999).  
Other covariates that were tested in statistical models due to potential effects on 
both informal costs and antidementia medications included the person with dementia’s 
place of residence and gender. With respect to gender, prior research has reported that 
males demonstrate greater variability in treatment response to antidementia medications 
than females (illar-Fernadez, Bjerrum, Feja, & Rabanaque, 2009). Place of residence may 
reflect severity of dementia as persons living in assisted living centers may experience 
more NPS and potentially medication use. Place of residence was updated at each visit 
and coded based on private home, assisted living, nursing home. The current study 
included individuals living in the community and in assisted living centers and excluded 
nursing home residents, due to residents in a nursing facilities incurring formal costs, not 
informal costs. 
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Statistical Analysis  
Linear mixed effect models were used to examine the association between 
antidementia medications (predictor or independent variable) and the informal costs of 
dementia care (outcome or dependent variable). Linear mixed models can accommodate 
various characteristics of data that are correlated (multiple measures for each participant), 
when the independent variable groups are uneven (antidementia medication use versus no 
use), there are an unequal number of measurements for participants, and the 
measurements are not taken at fixed time points (Verbeke & Molenberghs, 2000), all 
characteristics that are present in DPS. Use of each medication type (antidementia, 
psychotropic, anticholinergic) was used as a time varying variable as updates of 
medications were obtained at each visit. Additional covariates tested included dementia 
severity (time varying CDR), general health (time varying GMHR), gender, and 
participant place of residence (time varying). To establish the best final model, model fit 
was assessed using -2 log likelihood, comparing more complex models (addition of 
covariates sequentially) to less complex models (lacking the covariate). Significance 
level for model fit was p < 0.05. 
Because cost distributions tend to be highly skewed, a gamma logarithmic link 
function was used, which has been previously applied to the DPS data when estimating 
costs (Rattinger et al., 2015). The gamma distribution is used for positively skewed data 
that does not have negative values (Grover, Sabharwal, & Mittal, 2013). Thus, the 
gamma model estimates are exponentiated to facilitate interpretation. For example, a 
hypothetical result might be that AD has a beta of approximately .65 compared to the 
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reference category of other dementia. Exponentiating this value yields a exp(beta) of 2, 
which can be interpreted as AD dementia having twice the cost of other dementias. 
Finally, as antidementia medications have different effects according to stages of 
dementia severity (Atri, 2011), I restricted the sample to only participants with mild 
dementia (CDR global score = 1 or less) at baseline. 
 
Results 
 
 
Sample Characteristics 
A total of 328 participants were identified with dementia from the CCSMA and 
enrolled into the DPS. The participants included in the sample only differed significantly 
from the excluded participants in the daily informal costs, with the 12 excluded 
participant’s minimum cost of $0.01 and maximum cost of $318.13 (Table 2.2). As 
statistical models with log-link functions are unable to handle 0, the dollars were 
transformed such that $.01 was added to all values prior to analyses. Thus, the actual 
range of costs would be $0 and $318.12. 
Preliminary analyses showed no significant difference in the use of antidementia 
medication between persons with AD compared to those with other dementias (Table 
2.3). Thirty-nine participants were excluded from the sample because they resided in a 
skilled nursing facility. Of the remaining 289, eight were excluded due to missing 
medication data and an additional four persons were excluded due to missing CDR data. 
The final number of participants included in the analyses was 277. 
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Table 2.2 
 
Baseline Characteristics of Included Versus Excluded in Sample 
 
 
Characteristics 
Included (N = 277) 
───────────────── 
Excluded (N = 12)  
────────────── 
 
 Fisher’s 
exact 
 
t N % M SD N % M SD 2 
Female 147 53.1   5 55.6   .02   
Residence            
 Home 214 77.3   6 66.7   .55   
 Assisted living 63 22.7   3 33.3      
Using antidementia meds  55 19.9   1 25.0   .07   
Using psychotropic meds 145 52.3   1 25.0   1.18   
Using anticholinergic meds 56 20.2   0 0.0    3.56  
GMHR health+            
 Fair/poor 51 18.4   2 22.2   .08   
 Good/excellent 226 81.6   7 77.8      
CDR+            
 Mild 219 79.1   4 100.0    1.86  
 Moderate/severe 58 20.9   0 0.0      
Age at baseline   85.6 5.6   88.1 6.2   1.51 
Education   13.4 2.8   13.6 2.7   .20 
Age at dementia onset   82.2 5.8   84.2 7.6   1.13 
Dementia duration in years   3.4 1.9   3.9 2.0   .97 
Daily cost in Utah   41.8 80.0   111.5 145.2   2.22* 
+ Note these covariates were further collapsed because of low frequency in the CDR and GMHR cells. 
* Significant differences between at p < .05. 
** Significant differences between at p < .01. 
 
 
Out of the total sample of participants, 40.5% taking antidementia medication 
were also taking psychotropic medication, 18.5% taking antidementia medication were 
also taking a level two or three anticholinergic medication, and 36.1% taking 
psychotropic medication were also taking a level two or three anticholinergic medication. 
For the subsample of 219 participants with mild dementia severity at baseline, 30.7% 
were taking antidementia medication throughout the study, 58% were taking 
psychotropic medication throughout the study, and 22.6% were taking a level two or 
three anticholinergic medication throughout the study. Approximately 26.3% of females  
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Table 2.3 
 
Baseline Characteristics of Sample: AD Versus Not AD 
 
 
Characteristics 
AD (N = 199) 
───────────────── 
Not AD (N = 78)  
────────────── 
 
 Fisher’s 
exact n % M SD n % M SD 2 
Female 113 56.8   34 43.6   3.92*  
Residence           
 Home 147 73.9   67 85.9   4.61*  
 Assisted living 52 26.1   11 14.1     
Using antidementia meds  45 22.6   10 12.8   3.37  
Using psychotropic meds 106 53.3   39 50.0   .24  
Using anticholinergic meds 38 19.1   18 23.1   .55  
GMHR health+           
 Fair/poor 29 14.6   22 28.2   6.93**  
 Good/excellent 170 85.4   56 71.8     
CDR+           
 Mild 155 77.9   64 82.1   .59  
 Moderate/severe 44 22.1   14 17.9     
Age at baseline   86.2 5.7   84.0 4.9  2.98** 
Education   13.4 2.9   13.5 2.6  -.19 
Age at dementia onset   82.8 5.9   80.7 5.2  2.73** 
Dementia duration in years   3.4 1.9   3.3 1.6  .39 
Daily cost in Utah   39.5 78.1   47.8 84.9  -.77 
+ Note these covariates were further collapsed because of low frequency in the CDR and GMHR cells. 
* Significant differences between at p < .05. 
** Significant differences between at p < .01. 
 
 
and 32.9% of males were using antidementia medication at any time throughout the study 
compared to 73.7% of females and 67.1% of males never using antidementia medication 
throughout the study (2 = 6.01, df = 1, p = .015). For the subsample of 219 participants 
with mild dementia severity at baseline, approximately 28% of females and 33% of males 
were using antidementia medication at any time throughout the study compared to 72% 
of females and 67% of males never using antidementia medication throughout the study 
(2 = 2.91, df = 1, p = .096). Figure 2.1 displays the duration of antidementia medication  
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Figure 2.1. Participants’ pattern of antidementia medication use over time.  
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use of those individuals who were ever on the medication in the whole sample. The y-
axis shows the count of participants in each group, (started before baseline, n = 65, 
started after baseline, n = 35). For each subject, the dots represent each visit and the lines 
represent the time between visits, with green indicating antidementia medication use, red 
indicating no antidementia mediation use, and blue indicating unknown antidementia 
medication use. For example, the second listed participant that started using antidementia 
medication after baseline was not using antidementia medication at the first visit, started 
using antidementia mediation at the second visit, discontinued antidementia medication 
use at the third visit, used antidementia medication between visits three and four, and 
finally did not use antidementia medication for remainder of the study time. The figure 
displays a majority of participants who were on antidementia medication at baseline, 
continued using it for the duration of the study. The longest a participant was on 
antidementia medications was approximately eight years.  
Of the participants who ever used antidementia medication, 41.1% progressed to 
residing in assisted living compared to 33.7% who never used antidementia medications 
(2 = 1.42, df = 1 , p = .233). Participants who ever took antidementia medication were of 
similar heath, with 49.5% of poor or fair heath status compared to 54.7% who never used 
antidementia medications (2 = .66, df = 1, p = .417). Approximately 76.8% of 
participants who ever took antidementia medications progressed to moderate or severe 
CDR severity ratings compared to 44.2% who never used antidementia medications (2 = 
26.46, df = 1, p < .001). 
Overall, the daily informal costs for milder stages of dementia were lower than for 
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severe dementia. Figure 2.2 displays the median daily informal cost by severity of 
dementia at baseline: for mild dementia estimated informal cost was $9.92, for moderate 
dementia $30.02, and for severe dementia $46.99.  
Over time, there was substantial variability in costs for a subset of the sample. 
Figure 2.3 displays person specific trajectories of informal costs over time, with the blue 
line indicating the moving average or general trend of the data and the shaded grey region 
indicating the 95% confidence band. There is higher density of person specific 
trajectories near zero informal costs compared to informal costs greater than or equal to 
$100. There were 180 participants who had informal costs below $20 at baseline and an 
additional 63 participants had informal costs below $100 at baseline. 
 
Association of Antidementia Medications  
and Costs 
Over time, informal costs did not change significantly (expβ = 1.03, p = .456). 
Figure 2.2. Bar graph of informal costs by dementia severity at baseline.  
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Figure 2.3. Person-specific plot of daily cost over time. 
 
 
Use of antidementia medications was not significantly associated costs (expβ = .80, p = 
.158). With the inclusion of significant covariates, the final model showed use of 
antidementia medication was not associated with informal costs (expβ = .79, p = .090). In 
examining gender differences, gender was entered as a covariate, and was not significant 
(expβ = .74, p = .107); an interaction between gender and antidementia medication use 
was also tested and was not significant (expβ = .72, p = .298). Only dementia severity, 
measured by CDR-SB, was significantly associated with an increase (18%) in informal 
costs (Table 2.4).  
When restricting the sample to only include the participants with mild dementia at 
baseline (N = 219), use of antidementia medications was associated with 28% reduction 
in informal costs (expβ = .72, p = .039). Again, dementia severity, measured by CDR-SB, 
was significantly associated with a 21% increase in informal costs (Table 2.4).  
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Table 2.4 
 
Mixed Models of Utah 2015 Cost Value 
 
 
 
Parameter 
Final model entire sample  
(N = 277) 
────────────────────────
Model with baseline mild severity  
(N = 219) 
─────────────────────── 
Exp(β) df p 
95% confidence 
lower upper Exp(β) df p 
95% confidence 
lower upper 
Intercept 12.57 1 < .001 8.92 17.72 11.90 1 < .001 7.86 18.00 
Time (years) .99 1 .746 .93 1.06 .98 1 .636 .9.1 1.06 
Taking antidementia meds .79 1 .090 .60 1.04 .72 1 .039 .53 .98 
CDR-SB  1.18 1 <.001 1.14 1.22 1.21 1 <.001 1.14 1.27 
 
 
 
Discussion 
 
This project examined the informal costs of dementia care in a community-
dwelling, population based sample of persons with dementia. While the results of the 
study did not find a statistically significant effect in the overall sample of participants, 
results from restricting the sample to only those with mild dementia at baseline found 
antidementia medication use was significantly associated with a 28% decrease in 
informal costs. These results suggest that antidementia medications are most effective in 
reducing the informal costs of care in early dementia and perhaps less so as severity 
increases. Fillit and Hill (2005) reviewed the effects of antidementia medications on costs 
of dementia care. This review included three RCTs, two of which found total cost savings 
associated with antidementia medication use, but the amount of savings differed due to 
different study settings (Europe and U.S.) and differences in assumptions of hours spent 
caregiving (Fillit & Hill, 2005). Fillit and Hill also found five studies modeling projected 
cost savings when using antidementia medication. All studies took place in the U.S. or 
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Canada and evaluated ChEIs cost effectiveness (Fillit & Hill, 2005). Two of these studies 
evaluated total costs, with results ranging from $73 in savings at two years for a person 
with mild AD to $2290 in savings at two years for a person with moderate AD, both of 
which 1999 monetary values (Fillit & Hill, 2005). A potential difficulty in comparing 
these two studies is that they assessed different ChEIs, donepezil and rivastigmine. The 
Fillit and Hill (2005) review yielded three retrospective studies based on claims made to 
managed care organizations in the U.S. (e.g., Medicare). These retrospective studies 
evaluated total costs of care with donepezil treatment. Results ranged from total cost 
savings of $579 to $3,891 at 12 months (monetary values from years 1997 to 1999) (Fillit 
& Hill, 2005). This review (Fillit & Hill, 2005) is useful in showing total cost benefits of 
using antidementia medications, but does not specifically address potential informal cost 
benefits. 
Of note, is the small number of participants in this study using antidementia 
medications (29.5% of the overall sample). This limited sample may have resulted in 
limited power to detect a significant association. Nonetheless, the frequency of 
antidementia medication use reported in the DPS is similar to rates reported in a large, 
nationally representative sample. Gruber-Baldini, Stuart, Zuckerman, Simoni-Wastila, 
and Miller (2007) evaluated a nationally representative sample of 12,697 persons with 
dementia from a Medicare database in 2002, which was also the start of the DPS. Results 
found that approximately 24.7% of individuals reported using antidementia medications, 
which is slightly lower than the usage reported in the DPS sample (Gruber-Baldini et al., 
2007).  
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As expected, greater severity of dementia was associated with higher informal 
costs. Other studies concur with these findings. For example, Wolstenholme et al. (2002) 
followed 100 participants with AD for up to 11 years who were enrolled from clinics in 
the UK to assess overall costs of care and disease severity as measured by the Mini-
Mental Status Exam (MMSE) and the Barthel ADL Index. Results found both the MMSE 
and Barthel ADL Index were significant predictors of increases in informal costs of care 
(Wolstenholme et al., 2002). Rapp et al. (2012) similarly reported that participants with 
AD living in a French community had greater informal costs with decreases in cognition, 
more problems with completing ADLs, and more NPS (Rapp et al., 2012). Of studies 
taking place in the U.S., Zhu et al. (2006a) followed 170 people with AD for up to seven 
years in the Predictors Study measuring disease severity with the MMSE and Blessed 
Dementia Rating Scale (functional symptoms). Results found that worse cognitive and 
functional status led to an increase in use of informal care. Additional results from Zhu et 
al. (2008) using 172 individuals who were followed for up to 4 years in the Predictors 
Study found that level of dependence was associated with an increase in caregiving time, 
which would in turn predict higher informal costs.  
Dementia severity has been further assessed with DPS data by Rattinger et al. 
(2015). Results found informal costs increased with dementia severity, approximately 
18% per year after onset and 5% to 8% per year when holding baseline severity constant 
(Rattinger et al., 2015). Additionally, Rattinger et al. (2016) evaluated 217 DPS dyads for 
cost differences based on the closeness of the caregiver and care-recipient relationship. 
Results found that higher relationship closeness was associated with 24% lower informal 
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costs (Rattinger et al., 2016). These studies demonstrate important findings within this 
dataset, as well as, contributions to modifiers of informal costs. 
 The current study is significant because there is no known research on the 
longitudinal effect of antidementia medication specifically on informal costs. A main 
strength of the current study is that it is population-based and longitudinal, which may 
make the results more generalizable to persons with dementia living in the community. 
Another advantage of this study is DPS had high participation rates (85% initial 
enrollment) and high ongoing participation rates at follow-up (95-100% excluding 
nonparticipation due to death). Another advantage of this study is that the method used to 
calculate informal cost allowed for cost estimates to be generalized throughout Utah.  
 A potential limitation of this study is related to using all forms of dementia instead 
of specifically using AD or VaD. Using heterogeneous forms of dementia may influence 
how effective antidementia medications are on symptoms, and certain forms of dementia 
also may require more or less informal care than others. The rates of antidementia use can 
differ between types of dementia (e.g., Table 2.2), although the frequency of use did not 
differ in this sample. Additionally, individual antidementia medication types were not 
examined due to low frequency of use. Finally, the homogeneous population of Cache 
County, including being White and the majority of individuals being members of The 
Church of Jesus Christ of Latter-day Saints (LDS), may limit generalizability. These 
factors can influence the participants’ or caregivers’ behaviors, for example, family time 
and relationships are valued and emphasized in this religion, which may have affected 
amount of time-spent caregiving or amount of time reported caregiving.  
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  Future studies may evaluate other factors that may contribute to the cost of 
informal dementia care, particularly factors that can be targeted for change. For example, 
much of the literature points to dementia severity affecting informal costs, but current 
treatments do not allow for much change in dementia severity. Further research should 
find ways to improve dementia severity, particularly with cognitive and functional status 
(Rapp et al., 2012; Wolstenholme et al., 2002; Zhu et al., 2006a) or the use of devices to 
promote functioning, such as electronic reminding or monitoring devices (Riikonen, 
Makela, & Perala, 2010). Other factors have also been associated with lower informal 
costs, including caregiver relationship closeness to the care-recipient (Rattinger et al., 
2016). Caregiver closeness is a modifiable factor that has impact on informal cost, but 
further research is needed to examine aspects of the “closer” relationships and how these 
relationships translate to the use of environmental supports and care-related behaviors. In 
summary, the results of this study did not find that antidementia medications reduced the 
costs of informal dementia care in a population-based sample, but that there are several 
identified avenues for future research. 
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CHAPTER 3 
STUDY 2: NEUROPSYCHIATRIC SYMPTOMS AND  
ANTIDEMENTIA MEDICATIONS 
 
Abstract 
 
Pharmacological treatments for dementia include cholinesterase inhibitors and N-
methyl-D-aspartate receptor antagonists (antidementia medications). These antidementia 
medications are associated with a delay in the progression of the cognitive and functional 
symptoms, but studies of the effects of antidementia medications on neuropsychological 
symptoms (NPS) show varying results. This project used extant data from the 
longitudinal, population-based Cache County Study on Memory and Aging (CCSMA) 
and the Dementia Progression Study (DPS), which included permanent residents aged ≥ 
65 of Cache County, Utah. Medication use was based on inspection of each participant’s 
medications and interview; NPS were estimated using the Neuropsychiatric Inventory 
(NPI). Linear mixed models were used to assess the association between antidementia 
medications and NPS. Results indicated that use of antidementia medications was 
associated with a 28% increase in NPS (expβ = 1.28, p < .001). However, this association 
was no longer significant with the inclusion of covariates, specifically, the use of 
psychotropic medications. Use of any psychotropic medication was significantly 
associated with a 30% increase in NPI score. Overall, antidementia medication use may 
not significantly reduce NPS, but the use of antidementia medications may reflect 
patterns of use that are prompted by severity of dementia and NPS.  
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Introduction 
 
Tacrine was the first cholinesterase inhibitor (ChEI) approved by the U.S. Food 
and Drug Administration (FDA) in 1993, but due to adverse side effects (hepatotoxicity), 
it is no longer on the market (Atri, 2011). Since then, several other antidementia 
medications have received FDA-approval including the ChEIs donepezil (Aricept), 
galantamine (Razadyne), rivastigmine (Exelon), and the N-methyl-D-aspartate (NMDA) 
receptor antagonist, memantine (Namenda; Atri, 2011). There has not been substantial 
evidence to show superior efficacy of one ChEI over another (Atri, 2011). To date, 
studies have shown ChEIs are more effective in treating mild AD, while combination 
treatment (ChEI + NMDA) is beneficial over monotherapy (ChEI or NMDA alone) in 
moderate to severe stages of AD (Atri, 2011).  
A recent literature review studied antidementia medication efficacy in both short-
term randomized control trials (RCT) and long-term observational studies (LTOS). It 
found that in short-term RCT’s, ranging from six months to one year, antidementia 
medications improved or decreased the rate of cognitive decline among persons with AD, 
while the LTOS studies found the persistence of medication use reduced cognitive, 
functional, and global decline among persons with AD (Rountree et al., 2013). The 
results from LTOC studies also showed that combination therapy (ChEI and memantine) 
was superior to ChEI monotherapy across the spectrum of severity in AD (Rountree et 
al., 2013). These results show that antidementia medications can be advantageous to the 
progression of cognitive and functional decline in dementia in the short and long term.  
It is less clear, however, if antidementia medications are also effective in 
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decreasing the occurrence of neuropsychiatric symptoms (NPS). NPS are common over 
the course of dementia (Cummings, 1997; Tschanz et al., 2011) and often stressful and 
burdensome to caregivers (Rymer et al., 2002). A number of studies have examined the 
effects of antidementia medications on NPS, the results of which have been summarized 
in reviews and meta-analyses. Grimmer and Kurz (2006) conducted a systematic review 
of studies examining antidementia medications and NPS, with the average duration of 
these studies being 20 weeks and ranging from 6 to 52 weeks. In their review, only two 
out of the 14 studies (six tacrine, six donepezil, and two galantamine) found statistical 
significance of antidementia medications reducing NPS in the treatment group over the 
placebo group (Grimmer & Kurz, 2006). Additionally, in nine of the 14 studies, 
psychotropic medications were also being used by 36-62% of individuals, making it 
difficult to infer whether any beneficial effects were attributable to antidementia 
medications or psychotropic medications (Grimmer & Kurz, 2006). A more recent 
systematic review by Rodda et al. (2009) of 14 randomized, placebo-controlled trials 
(nine donepezil, three galantamine, and two rivastigmine) reported that three of the 
studies found a decrease in NPS. The median length of these studies was 24 weeks 
(ranging from 12 to 170 weeks), which is a similar length to studies covered in previous 
reviews (Rodda et al., 2009). One limitation noted in the Rodda et al. review was that 
many of the studies were not specifically designed or had enough power to detect 
changes in NPS. Some of the studies included also had a short duration of treatment, 
which could impact the efficacy of antidementia medication effects. Another limitation, 
similar to that reported in other reviews (Grimmer & Kurz, 2006), is that many studies 
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reported high rates of psychotropic medication use in the participants for which there was 
no statistical control. One strength of the review was its inclusion of studies that did not 
allow participants to use medications with cholinomimetic or anticholinergic effects 
which can decrease the effectiveness of antidementia medications (Rodda et al., 2009).  
Antidementia medications may differentially affect NPS. In their review, 
Cummings and colleagues identified that eight of 15 AD clinical trials found differences 
in antidementia mediations affecting NPS, with the studies having a median duration of 
six months and ranging from three months to two years (Cummings et al., 2008). Reports 
found positive outcomes, with mood symptoms and apathy responding better to ChEIs 
and irritability and agitation responding better to memantine (Cummings et al., 2008). 
Eight studies that found ChEIs or memantine to significantly decrease NPS allowed 
participants to be taking psychotropic medication, with the one other study not indicating 
whether psychotropic medication was allowed (Cummings et al., 2008). The use of 
psychotropic medications may have confounded these results as both types of 
medications can affect NPS. Studies, within this review, reporting non-significant results 
on NPS were more likely to involve institutionalized individuals who had few behavioral 
disturbances at baseline, which may have affected the ability of staff to identify 
behavioral changes at milder levels of severity (Cummings et al., 2008). As noted by the 
authors, one limitation of some of the studies was the substantial variability of severity 
levels of patients in the trials, with the majority of studies including individuals with 
severe dementia.  
The importance of controlling for psychotropic medications in analyses 
40 
 
examining the association of antidementia medications and NPS is underscored by 
prescription patterns of psychotropic medications as reported in a Swedish study by 
Gustafsson, Sandman, Karlsson, Gustafson, and Lovheim (2013). This study, which 
enrolled 2,019 institutionalized individuals with cognitive impairment, found significant 
associations between psychotropic drug use and specific NPS. Gustafsson et al. found 
that antipsychotic medication use was associated with aggressive behavior, verbally 
disruptive behavior, passivity, hallucinations, and disorientation; anxiolytic drug use was 
associated with verbally disruptive, restlessness, inappropriate behaviors, and depressive 
symptoms; hypnotic and sedative medication use was associated with verbally disruptive 
and inappropriate behaviors; and antidepressant medication use was associated with 
verbally disruptive and depressive symptoms (Gustafsson et al., 2013). Gustafsson et al. 
demonstrated how psychotropic medications contribute to a decrease in NPS, but also 
how different NPS are more likely to have certain psychotropic medications prescribed. 
 While previous reviews (Grimmer & Kurz, 2006) reported that antidementia 
medications may improve NPS (at least in a few studies), still there were inconsistencies 
across studies with several showing no effect. Advantages of the RCTs discussed in these 
reviews include the randomization of treatment and control groups and control for 
participant characteristics, while limitations include short duration of study, participants 
frequently having severe dementia, and that many of the studies being conducted in 
institutional settings. 
 Given the uncertain efficacy of antidementia medications on NPS in dementia, the 
current project examined whether antidementia medications decreased NPS in dementia 
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in a population-based sample from the Cache County Study on Memory in Aging 
(CCSMA). There are several advantages of this population-based study including follow-
up of incident (newly identified) persons with dementia, and up to 10 years of follow-up. 
I examined whether persons with dementia taking antidementia medications would 
exhibit less severe neuropsychiatric symptoms than those who were not taking 
antidementia medications while controlling for psychotropic and anticholinergic 
medications. The latter was examined as these medications may enhance symptoms of 
dementia (e.g., cognitive impairment; Carriere et al., 2009). 
 
Methods 
 
Sample 
 This project used extant data from the Cache County Study on Memory in Aging 
(CCSMA; 1995-2007) and the ancillary study, the Dementia Progression Study (DPS; 
2002-2013). The sample of persons with dementia was identified from the longitudinal, 
population-based CCSMA, which included permanent residents aged ≥ 65 of Cache 
County, Utah. The CCSMA examined the prevalence, incidence, and risk factors of 
dementia in this U.S. county, which has been recognized for its residents’ longevity. In 
Wave 1, CCSMA enrolled 5,092 (89.7%) of the eligible individuals in the county 
(Breitner et al., 1999) and subsequently conducted three additional triennial waves of 
dementia screening and evaluation described briefly below.  
 According to Breitner et al. (1999), the participants were given the 100-point 
Modified Mini-Mental State Examination (3MS) cognitive screener in the first stage. 
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Some of the participants (386) received a proxy interview if they could not complete the 
3MS, scored below a 15 on the orientation subset of the 3MS, scored below 60 on the 
3MS, or if the individual was otherwise deemed unreliable by the interviewer (Breitner et 
al., 1999). If an individual’s 3MS score was below 87 or if he/she was a member of a 
designated subsample to complete all evaluation stages, a knowledgeable informant 
completed a dementia questionnaire (DQ) with a technician. The DQ is a 50-item semi-
structured interview of the symptoms of dementia and general medical history, the results 
of which were then rated for degree of cognitive impairment by a neuropsychologist and 
geriatric psychiatrist. Individuals with ratings of “questionable” or “probable” dementia 
(Wave 1) or “moderate impairment,” “questionable,” or “probable” dementia (Wave 2) 
were asked to undergo a clinical assessment, which was conducted by a research nurse 
and psychometrist. In the clinical assessment, the research nurse interviewed an 
informant about the participant’s medical history and current medications, and the 
participant underwent a physical examination including assessment of blood pressure and 
a standardized neurological examination. The psychometrist administered a battery of 
neuropsychological tests to the participant (Tschanz et al., 2000). Additionally, the 
knowledgeable informant completed the NPI. 
 A neuropsychologist, geriatric psychiatrist, examining nurse, and psychometrist 
reviewed the clinical assessment results. A preliminary diagnosis of dementia was given 
if meeting the criteria from the Diagnostic and Statistical Manual-III-R (DSM-III-R; 
APA, 1987). Individuals, who received a classification of dementia or “mild/ambiguous” 
(prodromal AD), were sent for follow-up laboratory testing and neuroimaging (complete 
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blood counts, routine chemistries, serum B-12, folate, thyroid function test, urinalysis, 
and Magnetic Resonance Imagining (MRI) or Computed Tomography (CT) scan). 
Persons with suspected dementia were examined at their place of residence by a geriatric 
psychiatrist who repeated the neurologic examination, Mini-Mental State Exam (MMSE), 
and clinical history. After a review of all available clinical exams, a panel of expert 
clinicians consisting of geriatric psychiatrists, a neurologist, neuropsychologists, and a 
cognitive neuroscientist assigned a final diagnosis (Breitner et al., 1999). A diagnosis of 
AD was given according to the National Institute of Neurological and Communicative 
Diseases and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA; McKhann et al., 1984). A Vascular Dementia (VaD) diagnosis was given based 
on the National Institute of Neurological Disorders and Stroke-Association Internationale 
pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) criteria 
(McKhann et al., 1984). Diagnoses of other dementias followed standard research 
criteria. Additionally, age of dementia onset (age at which the individual met DSM-III-R 
criteria for dementia), severity of dementia using the Clinical Dementia Rating (CDR; 
Hughes et al., 1982), and rating of overall health with the General Medical Health Rating 
(GMHR; Lyketsos et al. (2005) were assigned. Persons with dementia completed a 
clinical assessment 18 months later to clarify the diagnosis (Breitner et al., 1999).  
 The CCSMA identified 942 cases of dementia from the four waves of dementia 
ascertainment conducted in 1995, 1998, 2002, and 2005. Each of the waves consisted of a 
similar protocol described above with the exception of modified cut-off points on the 
3MS and dementia questionnaire (DQ), and with Waves 3 and 4 excluding the DQ stage.  
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 From 2002 to 2007, the individuals who were identified with incident dementia in 
the CCSMA were invited to enroll in the Dementia Progression Study (DPS; Tschanz et 
al., 2011). The DPS was a longitudinal study running from 2002 to 2013 and examined 
factors that affect the rate of dementia progression in persons with AD and other 
dementias. A research nurse and psychometrist conducted in-home evaluations to the 
participants and their caregivers approximately every 6 to 8 months. The in-home 
evaluations consisted of a 45- to 60-minute neuropsychological test battery, brief 
neurological and physical examination, assessment of functional abilities using the CDR 
and Dementia Severity Rating Scale (DSRS; Clark & Ewbank, 1996), interview of health 
and psychiatric conditions, medication review and assessment of the caregiver’s well-
being and time spent providing care (Tschanz et al., 2011). The current project used the 
data obtained from both the CCSMA and DPS in examining the effects of antidementia 
medications on NPS in dementia.  
 
Procedures 
 For this research question, all persons with dementia identified from the CCSMA 
& DPS were considered for analyses (N = 942), which included both prevalent and 
incident cases. Because of potential differences between prevalent and incident cases, 
subjects were coded as either having been identified as a prevalent or incident case and 
differences between these two groups were examined. 
Independent/predictor variables. All medication use, including antidementia 
medications, was recorded by the research nurse who inspected all the medications taken 
by the individual with dementia at the diagnosis visit of the CCSMA, as well as all 
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follow-up visits of the DPS. Because information on medication usage between visits was 
not available, medications used at consecutive visits was assumed to be taken throughout 
the time between visits. Medication use was confirmed with visual inspection of the vials 
(Medical Record, see Appendix A) and for persons living in nursing homes, confirmed 
with a Medication Administration Record, with the following methods described 
previously (Zandi, 2005). Medications were reviewed and coded using the Mosby Drug 
Reference System (Skidmore-Roth, 2009). Subjects were classified according to use (or 
no use) of antidementia medications (CHEIs or NMDA receptor antagonists). 
Medications tested as covariates included: any psychotropic medications (antipsychotic, 
antidepressant, and anxiolytic/sedative-hypnotic, or mood stabilizing medications), as 
well as medications with anticholinergic effects. Anticholinergic medications were 
included as a covariate because of potential adverse effects on cognition (Carriere et al., 
2009). Anticholinergic medications were classified using The Anticholinergic Cognitive 
Burden Scale (ACBS, see Appendix B), which is a list of anticholinergic medications 
ranked from one to three with level one meaning possible anticholinergic and levels two 
and three indicating definite anticholinergic properties (Campbell et al., 2010). Any 
medications classified, as an anticholinergic at a level two or three were entered as a 
covariate.  
The other covariates that were tested include gender, place of residence 
(community, assisted living, and nursing home), dementia duration, dementia severity, 
and overall health. With respect to including gender, residence, and dementia duration as 
covariates, the literature supports a potential need to examine their effects. For example, 
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gender effects have been shown in prior research, with males demonstrating greater 
variability in treatment response to antidementia medications than females (illar-Fernadez 
et al., 2009). Place of residence may reflect severity of dementia and therefore NPS and 
medication use, with more severely impaired individuals likely living in institutionalized 
settings. Place of residence was updated at each visit and coded based on private home, 
assisted living, nursing home. Since dementia was identified at varying times post-onset, 
duration of dementia was entered as a covariate in statistical models.  
  The CDR (see Appendix C) is a rating based on a semi-structured interview 
administered to the caregiver and participant and estimates the severity of cognitive and 
functional impairments across six domains: memory, orientation, judgment and problem 
solving, community affairs, home and hobbies, and personal care (Hughes et al., 1982). 
The CDR global scoring method was used with a scale ranging from 0 = no impairment, 
0.5 = questionable impairment, 1 = mild impairment 2 = moderate impairment, 3 = severe 
impairment, 4 = profound impairment, and 5 = terminal (Hughes et al., 1982). Due to 
limited numbers of participants falling in the mild and severe ranges, data were collapsed 
into 0, .5, 1 = mild impairment, 2 = moderate impairment, 3, 4, 5 = severe impairment. 
The CDR has moderate to high inter-rater reliability with a kappa = 0.62 (Rockwood et 
al., 2000). 
Overall health status was also used as a covariate, and assessed using the General 
Medical Health Rating (GMHR, see Appendix D), which provides a global rating of an 
individual’s health. The rating is based on information obtained at each visit from the 
medical interviews conducted by the research nurse, a review of medications and brief 
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physical and neurological exams (Lyketsos et al., 2005). In assigning the ratings, 
consideration is given to the number of conditions, acute or chronic status, and whether 
the conditions are controlled by treatments (Lyketsos et al., 2005). Based on this 
information, a geriatric psychiatrist and clinical assessment team assigned the individual 
a ranking from one to four: “excellent” (4), “good” (3), “fair” (2), or “poor” (1) (Lyketsos 
et al., 2005). The interrater reliability of the GMHR has been examined in a random 
sample of 150 participants of the Cache County Study and showed good inter-rater 
reliability, r = .704, p < .001 (Lyketsos et al., 2005). In other samples, the GMHR has 
demonstrated concurrent validity with number of medical diagnoses and medications as 
well as predictive validity in its association with mortality (Lyketsos et al., 1999). The 
inter-rater reliability of the GMHR in a separate sample was high in this study with a 
weighted kappa of .93 (Lyketsos et al., 1999).  
Outcome variable. The Neuropsychiatric Inventory (NPI, see Appendix E) was 
used to measure the type and severity of NPS, usually present in dementia (Cummings et 
al., 1994). The NPI-10 item version was used to assess NPS over the past month 
including delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, 
euphoria, disinhibition, and aberrant motor behavior (Cummings, 1997). The NPI was 
completed by a knowledgeable informant in the CCSMA or the caregiver in the DPS and 
was completed at each clinical assessment. The administration of the NPI consisted of a 
structured interview assessing whether the symptoms occurred. If a symptom was 
endorsed, the caregiver was asked to rate the frequency (4-point scale) and severity (3-
point scale) of the symptoms. The outcome variable was total NPI score, which was 
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calculated by summing the product of the frequency and severity scores across the 
domains.  
 Content validity of the NPI items was assessed by a group of 10 international 
experts in the field (geriatric psychiatry, behavioral neurology, and neuropsychology) 
who rated the screening questions as 1 = well assessed to 4 = poorly assessed, with each 
category besides aberrant motor behavior having a rating of less than 2 (Cummings, 
1997). Concurrent validity of the NPI was tested with the Behavioral Pathology in 
Alzheimer’s Disease (BEHAVE-AD) and Hamilton Rating Scale for Depression, with 
results showing no statistically significant differences between these assessments 
(Cummings, 1997). Convergent validity with the Apathy Evaluation Scale (apathy), Brief 
Psychiatric Rating Scale (delusions and hallucinations), Cohen-Mansfield Agitation 
Index (agitation), Cornell Scale for Depression in Dementia (depression) was moderate to 
strong in the four domains with depression having the strongest correlation, r = .61 and 
apathy having the weakest correlation, r = .31 (de Medeiros et al., 2010). The interrater 
reliability for each item was overall moderate to strong ranging from ICC = .50-.97 (de 
Medeiros et al., 2010). The NPI test-retest reliability was assessed over a 3-week time 
span and showed significant correlation with .79 for frequency and .86 for severity 
(Cummings, 1997).  
 
Statistical Analysis 
Linear mixed effect models were used to examine the association between 
antidementia medications (independent variable) and NPS (dependent variable). 
Antidementia medications were used as a time varying variable, as updates of 
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medications were acquired at each visit. First overall psychotropic medications were 
assessed as a covariate, then additional analyses evaluated the separate classes of 
psychotropic medication (antidepressants, antipsychotic, etc.) because research found that 
certain psychotropic medications may affect NPS differently (Rosenberg et al., 2012).  
In general, mixed models are recommended when the groups of participants are 
uneven, there are an unequal number of measurements for participants, and the 
measurements are not taken at fixed time points (Verbeke & Molenberghs, 2000), which 
are conditions present in the CCSMA and DPS. To establish the best final model, model 
fit was assessed using -2 log likelihood, comparing more complex models (addition of 
covariates sequentially) to less complex models (lacking the covariate). Significance 
level for model fit was p < 0.05. 
Due to the residuals of the NPI being positively skewed and the distribution of the 
NPI departing substantially from normal, the NPI total score was transformed by taking 
the natural log of the score. To account for scores of 0, a value of 1 was added to all 
scores as the natural log of 0 is undefined. This transformation produced a new 
distribution that more closely approximated a normal distribution. Appendix F shows NPI 
scores for each visit and Appendix G shows the natural log of NPI for each visit.  
UCLA Institute for Digital Research and Education explains that to facilitate 
interpretation of the mixed models, natural log estimates are exponentiated (Institute for 
Digital Research and Education [IDRE], 2016). For example, a hypothetical result might 
be that females have a beta of approximately .11 compared to the reference category of 
males. The predicted probability is achieved by exponentiating the beta value. The 
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exp(.11) is 1.12, which can be interpreted as females having 12% more severe NPS than 
males (IDRE, 2016).  
 
Results 
 
Sample Characteristics 
In the CCSMA, 942 participants were diagnosed with dementia, either in the 
prevalence or incidence waves. Of these, 11 had no measures from the clinical 
assessment and were diagnosed from review of medical records and/or autopsy results, 
leaving 931 available for analyses. The percentage of participants taking antidementia 
medications in the prevalent versus incident waves differed significantly at baseline (2 = 
19.86, df = 1, p < .001) with only 1.4% of prevalent cases using antidementia medications 
compared to 8.6% of incident cases using antidementia medications (Table 3.1). There 
were 10 participants with missing values for medications across prevalent or incident 
 
Table 3.1 
 
Baseline Number of Participants Using Antidementia Medications by Prevalent and 
Incident Cases and Dementia Type 
 
Dementia categories 
Using antidementia 
medication 
──────────── 
Not using antidementia 
medication 
────────────  
2 n % n % 
Prevalent dementia 5 1.4 343 98.6  
Incident dementia 49 8.6 524 91.4  
     19.86** 
Incident AD 39 10.0 352 90.0  
Incident other dementia 10 5.5 172 94.5  
     3.19 
* Significant differences between at p < .05. 
** Significant differences between at p < .01. 
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cases. Given the infrequent use of antidementia medications in prevalent cases, only 
incident dementia cases were used in the current analysis. An examination of incident 
dementia type by antidementia medication use revealed a somewhat higher percentage of 
participants with AD were taking antidementia medications (10%) than those with other 
dementia (5.5%); however this difference was not statistically significant (2 = 3.19, df = 
1, p =. 079). Thus, participants with any form of dementia were included in the analyses, 
but dementia type was tested as a covariate. Finally, the sample was further restricted to 
include those not missing data from the NPI (eight cases) and CDR (three cases) and 
antidementia medication usage (two cases) resulting in a final sample consisting of 569 
cases of incident dementia.  
In examining differences between participants included versus excluded in the 
analysis, those excluded were rated with more severe dementia, with 44.4% of moderate 
or severe dementia at baseline and only 17.4% of participants included in the analysis of 
moderate or severe dementia at baseline (Table 3.2).  
Table 3.3 shows the baseline characteristics of cases with incident AD compared 
to incident other dementias. Participants with other dementias were slightly younger 
compared to those with AD (t = 3.03, df = 567, p =. 003) and the mean age of dementia 
onset at baseline was slightly older in persons with AD compared to those with other 
dementia (t = 3.15, df = 567, p =. 002). There were significantly more females with AD 
(64.4%) compared to other dementias (51.9%). Persons with AD had significantly better 
health, with 63.7% rated as good or excellent health compared to 36.5% of persons with 
other dementia rated as good or excellent health at baseline.  
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Table 3.2 
 
Baseline Characteristics of Sample: Included in Analysis Versus Excluded 
 
 
Characteristics 
AD (N = 199) 
───────────────── 
Not AD (N = 78)  
────────────── 
 
 Fisher’s 
exact 
 
t n % M SD n % M SD 2 
Female 344 60.5   7 53.8   .23   
Dementia type            
 AD 388 68.2   7 53.8   1.20   
 Other 181 31.8   6 46.2      
Residence            
 Home 451 79.3   10 83.3   .12   
 Assisted living 58 10.2   1 8.3      
 Nursing facility 60 10.5   1 8.3      
Antidementia medication use 49 8.7   0 0    1.62  
Psychotropic medication use 223 39.5   2 22.2   1.11   
Anticholinergic medication use 101 17.9   2 22.2   .11   
Health status+            
 Poor/fair 256 45.0   2 16.7   3.82   
 Good/excellent 313 55.0   10 83.3      
CDR+            
 Mild 465 82.6   5 55.5   4.42**   
 Moderate/severe 98 17.4   4 44.4      
Age at baseline   85.2 6.1   86.5 6.6   -.78 
Education   13.3 3.0   13.4 3.3   -.15 
Age at dementia onset   83.5 6.3   85.2 6.5   -1.01 
Dementia duration in years   1.7 1.3   1.3 1.1   1.21 
Total NPI score   4.9 9.2   3.4 5.0   .37 
+ Note these covariates were further collapsed because of low frequency in the CDR and GMHR cells. 
* Significant differences between at p < .05. 
** Significant differences between at p < .01. 
 
 
 
NPI scores were highly variable over time. Figure 3.1 displays person-specific 
trajectories of total (raw, untransformed) NPI scores, with the bold line indicating the 
moving average or general trend of the data. When considered across the entire sample, it 
appeared that NPI scores slightly increased and then plateaued over time. The shaded 
grey region is the 95% confidence band. There is higher density of person specific 
trajectories with an NPI score near zero for measures obtained closer to baseline, with 
250 participants having a score of 0 at baseline.  
Out of the participants taking antidementia medication (20.8% of the total  
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Table 3.3 
 
Baseline Characteristics of Sample: Incidence AD Versus Incidence Other Dementia  
 
 
Characteristics 
AD (N = 199) 
──────────────── 
Not AD (N = 78)  
────────────── 
 
  
t n % M SD n % M SD 2 
Female 250 64.4   94 51.9   8.07**  
Residence           
 Home 312 80.4   139 76.8   7.88*  
 Assisted living 44 11.3   14 7.7     
 Nursing facility 32 8.2   28 15.5     
Health status+           
 Poor/fair 141 36.3   115 63.5   36.88**  
 Good/excellent 247 63.7   66 36.5     
CDR+           
 Mild 319 83.54   146 80.7   .69  
 Moderate/severe 63 16.5   35 19.3     
Antidementia medication use 39 10.1   10 5.6   3.18  
Psychotropic medication use 144 37.4   79 44.1   2.32  
Anticholinergic medication use 62 16.1   39 21.8   2.69  
Age at baseline   85.7 6.1   84.1 6.1  3.03** 
Education   13.3 3.1   13.3 3.0  -.03 
Age at dementia onset   84.0 6.2   82.2 6.2  -.91 
Dementia duration in years   1.7 1.3   1.8 1.4  3.15** 
Total NPI score   4.4 8.9   6.0 9.8  -1.91 
+ Note these covariates were further collapsed because of low frequency in the CDR and GMHR cells. 
* Significant differences between at p < .05. 
** Significant differences between at p < .01. 
 
 
sample), 100% were also taking psychotropic medication and 26.9% were taking a level 
two or three anticholinergic medication. Figure 3.2 displays the duration of antidementia 
medication use of those individuals who were ever on the medications. The y-axis shows 
the count of participants in each group. For each subject, the dots represent each visit and 
the line represents the time between visits, with green indicating antidementia medication 
use, red indicating no antidementia mediation use, and blue indicating unknown 
antidementia medication use. The figure shows that a majority of participants who were  
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Figure 3.1. Person-specific plot of individual NPI scores over time. 
 
on antidementia medication at baseline, continued using it for the duration of the study.  
Of the participants who ever used antidementia medication, 52.9% progressed to 
residing in assisted living or nursing facility compared to 40.9% who never used 
antidementia medications (2 = 5.54, df = 1 , p = .019). Participants who ever took 
antidementia medication were of similar heath, with 60.5% of poor or fair heath status 
compared to 62.2% who never used antidementia medications (2 = .12, df = 1, p = .728). 
Approximately 89.1% of participants who ever took antidementia medications progressed 
to moderate or severe CDR severity ratings compared to 84.7% who never used 
antidementia medications (2 = 1.45, df = 1, p = .229).  
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Figure 3.2. Participants’ duration of antidementia medication use. 
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Association Between Antidementia  
Medications and NPS 
Model building proceeded sequentially, adding variables one at a time. Except for 
the variable of interest, antidementia medications, covariates were retained if they 
enhanced the model fit. NPS significantly changed over time, with a 1-year increase in 
time indicating approximately 28% increase on the NPI (expβ = 1.28, p < .001). Use of 
antidementia medications was significantly associated with NPI such that using these 
medications had a 27% increase in NPI score (expβ = 1.27, p = .001). However, once use 
of psychotropic medication was included in the model, antidementia medications use was 
no longer significant. Retaining only significant terms that produced the most 
parsimonious model, the “final” model consisted of CDR, place of residence, dementia 
type, antidementia medications (though nonsignificant, retained as the variable of 
interest), and psychotropic medications (Table 3.4). Dementia duration was not added to 
the final model because it was highly correlated with CDR at r = .342, p < .001. CDR 
was chosen because it was more significantly correlated with NPI than dementia 
duration. Use of psychotropic medication was associated with a 30% increase in NPI 
score. Compared with mild dementia, moderate dementia was associated with 
approximately a 50% increase in total NPI and severe dementia with a 60% increase in 
total NPI. Participants residing in assisted living (compared to home) had approximately 
40% increase in total NPI. Participants with AD had 18% less severe NPI score than 
those with other dementias.  
 
 Ta
bl
e 
3.
4 
Fi
na
l N
PI
 M
ix
ed
 M
od
el
  
 
Fi
na
l m
od
el
 c
om
bi
ne
d 
ps
yc
ho
tro
pi
c 
m
ed
ic
at
io
ns
 
──
──
──
──
──
──
──
──
──
──
──
──
──
──
──
──
 
M
od
el
 w
ith
 o
nl
y 
an
tid
ep
re
ss
an
t a
nd
 a
nt
ip
sy
ch
ot
ic
 m
ed
ic
at
io
ns
 
──
──
──
──
──
──
──
──
──
──
──
──
──
──
──
──
──
──
 
 Pa
ra
m
et
er
 
Es
t. 
df
 
P 
95
%
 c
on
fid
en
ce
 
in
te
rv
al
 
Ex
p(
β) 
Es
t. 
df
 
P 
95
%
 c
on
fid
en
ce
 
in
te
rv
al
 
Ex
p(
β) 
In
te
rc
ep
t 
1.
07
 
64
6.
38
 
<.
00
1 
.9
3 
1.
22
 
2.
92
 
1.
10
 
61
5.
52
 
<.
00
1 
.9
6 
1.
24
 
3.
00
 
Ti
m
e 
(Y
ea
rs
) 
.1
7 
18
4.
46
 
<.
00
1 
.1
4 
.2
0 
1.
19
 
.1
7 
17
5.
90
 
<.
00
1 
.1
4 
.2
0 
1.
19
 
C
D
R
a  
 
 
 
 
 
 
 
 
 
 
 
 
 
M
od
er
at
e 
.4
0 
19
02
.6
0 
<.
00
1 
.2
8 
.5
1 
1.
49
 
.4
5 
15
26
.2
4 
<.
00
1 
.2
7 
.6
3 
1.
57
 
 
Se
ve
re
 
.4
7 
15
24
.4
3 
< 
.0
01
 
.2
9 
.6
5 
1.
60
 
.4
0 
18
99
.0
7 
< 
.0
01
 
.2
7 
.5
1 
1.
49
 
R
es
id
en
ce
b 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
ss
is
te
d 
liv
in
g 
.3
5 
15
72
.4
1 
<.
00
1 
.2
0 
.4
9 
1.
42
 
.0
3 
16
07
.1
1 
.7
62
 
-.1
4 
.2
0 
1.
03
 
 
N
ur
si
ng
 fa
ci
lit
y 
.0
4 
16
09
.4
8 
.6
24
 
-.1
3 
.2
2 
1.
04
 
.3
4 
15
62
.0
6 
< 
.0
01
 
.1
9 
.4
8 
1.
41
 
A
D
c  
-.2
0 
50
3.
68
 
.0
11
 
-.3
5 
-.0
5 
.8
2 
-.2
0 
50
0.
25
 
.0
11
 
-.3
5 
-.0
5 
.8
2 
U
si
ng
 a
nt
id
em
en
tia
 
m
ed
s 
.1
1 
14
60
.2
9 
.1
83
 
-.0
5 
.2
6 
1.
12
 
.2
4 
14
07
.2
9 
.0
01
 
.1
0 
.3
8 
1.
27
 
U
si
ng
 p
sy
ch
ot
ro
pi
c 
m
ed
s 
.2
6 
17
15
.7
9 
<.
00
1 
.1
4 
.3
9 
1.
30
 
 
 
 
 
 
 
U
si
ng
 a
nt
id
ep
re
ss
an
t 
m
ed
s 
 
 
 
 
 
 
.2
3 
14
67
.7
0 
<.
00
1 
.1
0 
.3
5 
1.
26
 
U
si
ng
 a
nt
ip
sy
ch
ot
ic
 
m
ed
s 
 
 
 
 
 
 
.1
8 
16
71
.0
3 
.0
36
 
.0
1 
.3
5 
1.
20
 
a C
om
pa
re
d 
to
 m
ild
 se
ve
rit
y.
 
b C
om
pa
re
d 
to
 re
si
di
ng
 a
t h
om
e.
 
c C
om
pa
re
d 
to
 o
th
er
 d
em
en
tia
.
57
58 
 
In more granular analyses, I broke down the combined psychotropic medications 
into separate drug classes of antidepressants, antipsychotics, sedative/hypnotic/ 
anxiolytics, and mood stabilizers/lithium medications. Out of the total sample at any 
time, 35.5% were on antidepressants, 10.1% were on antipsychotic, 11.9% were on 
sedative/hypnotic/anxiolytics, and .3% were on mood stabilizers/lithium medications. In 
the statistical model examining antidementia medications and informal care costs, entry 
of use of each psychotropic dug class revealed significant covariates for antidepressants 
and antipsychotic medications only (Table 3.4). In this model, use of antidementia 
medications was significantly associated with NPI such that using these medications had 
an approximately a 30% increase in NPI score (expβ = 1.27, p = .001). Of the specific 
drug classes, antidepressant medications were significantly associated with a 26% 
increase in NPI and antipsychotic medications were significantly associated with a 20% 
increase in NPI. 
 
Discussion 
 
In this study of persons with all cause dementia, as with previous work in persons 
with AD (Tschanz et al., 2011), NPS was found to increase in severity over time. The use 
of antidementia medication was significantly associated with the severity of NPS, but this 
association was confounded by use of psychotropic medications. Of those participants 
who were taking antidementia medications, 100% of participants were also taking a 
psychotropic medication. With respect to the direction of effect, where use of 
antidementia medications or psychotropic medications predicted worse NPS, it is likely 
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that both served as a marker of more severe dementia or neuropsychiatric symptoms that 
prompted participants and caregivers to seek treatment. The more specific model that 
separated the psychotropic drug classes yielded similar results as the overall psychotropic 
drug use in that use of antidementia, antidepressant, and antipsychotic medications may 
in this sample, reflect more severe dementia that prompted caregivers to seek more 
aggressive treatment. Rosenberg et al. (2012), provided an in-depth analysis on 
psychotropic medication use within this same sample, although restricting the sample to 
persons with AD only. That study found that the use of psychotropic medications was 
associated with worse NPS score, in particular, SSRIs and antipsychotic medications 
(Rosenberg et al., 2012). The authors suggested that the use of psychotropic medications 
could reflect severity of symptoms, or a less likely interpretation that these medications 
may also increase NPS. The potential effects of psychotropic medications (or 
antidementia medications) cannot be teased out within the scope of this observational 
study. While previously mentioned reviews (Grimmer & Kurz, 2006; Rodda et al., 2009) 
found that antidementia medications may improve NPS, the current study was not able to 
support these findings. Some of the studies discussed in the reviews did not find a 
beneficial effect of antidementia medications on NPS. The majority of the studies 
reporting a positive treatment effect of antidementia medications on NPS were RCTs, but 
many were of a short duration (ranging from 42 days to one year), did not account for 
psychotropic medication use, and restricted antidementia medication use to a specific 
ChEI and/or NMDA receptor antagonist.  
 Additional longitudinal studies have compared type of antidementia medication 
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used and effects on NPS. Cumbo (2005) examined 101 participants with mild to 
moderate AD in a randomized 18-month clinical trial examining the effects of 
rivastigmine, galantamine, and donepezil on NPS. Participants treated with rivastigmine 
had less severe and fewer NPS compared to those treated with donepezil; there were no 
significant differences in NPS between those treated with rivastigmine versus 
galantamine, or those treated with donepezil versus galantamine (Cumbo, 2005). More 
recently, Cumbo and Ligori (2014) compared 177 participants with AD in a 12-month 
RCT with the treatment of memantine, donepezil, rivastigmine, or galantamine. 
Statistically significant differences in NPS were found between baseline and 12-month 
follow-up for the participants treated with memantine, donepezil, or rivastigmine (Cumbo 
& Ligori, 2014). The percentage of improved NPI total scores for memantine was 41.6%, 
donepezil 38.1%, and rivastigmine 41.3%, compared to only a 31.7% improvement in 
total NPI score when participants were on galantamine (Cumbo & Ligori, 2014). Cumbo 
(2005) and Cumbo and Ligori (2014) provided important information about longer-term 
effects of ChEIs and NMDA receptor antagonist on NPS, though the studies did not 
address the issue of comorbid use of psychotropic medications. Specific type of 
antidementia medications were not examined in the current study due to limited sample 
size. 
Like numerous other studies, the current analyses found NPS associated with 
dementia severity. Thus, Stella, Laks, Govone, de Medeiros, and Forlenza (2016) 
evaluated 156 Brazilian AD patients and found that certain NPS were correlated with 
dementia progression, including apathy (.74), agitation (.72), psychosis (.59), affective 
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symptoms (.45), and sleep disturbances (.45). Zahodne, Ornstein, Cosentino, Devanand, 
and Stern (2015) found in the Predictors Study, a U.S. longitudinal study of AD, and 
found that psychosis, depression, and agitation were associated with cognitive decline. So 
as in the case of the current study, dementia severity was associated with worse NPS.  
A significant strength of the current study is the high participation rate over the 
course of CCSMA and DPS. CCSMA with 90% initial enrollment and DPS with 85% 
initial enrollment, not only had high turnout of participants but also very high ongoing 
participation rates at follow-up (e.g., DPS of 95-100% excluding nonparticipation due to 
death). Another advantage of this study was it being population-based, which may make 
it more generalizable to persons with dementia living in the community.  
This current study is particularly important because there is very limited research 
on antidementia medications on NPS with long follow-up times. Although the numbers 
of persons on antidementia medications was somewhat low (e.g., 20.8%), it is similar to 
the 24.7% reported in a nationally representative sample of 12,697 persons with dementia 
from a Medicare database (Gruber-Baldini et al., 2007). However, a more recent cross-
sectional study of Medicare data from 2008 evaluated medication usage in 52,754 
persons with dementia (Rattinger et al., 2013). This study found that approximately 
57.1% used antidementia medications over the course of the year. Annual usage of other 
medications covered by Medicare Part D in this sample was as follows: use 
of antidepressants of 56.4%, use of antipsychotics of 34.0%, and use of a mood stabilizer 
of 8.8%. The Rattinger et al. study showed higher usage of all the psychotropic drug 
classes compared to the medication usage in the current study and may suggest a trend of 
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increasing usage of antidementia medications, as well as, psychotropic medications over 
time. Both Gruber-Baldini et al. and Rattinger et al. studies were cross-sectional, 
while the current study evaluated antidementia medication use longitudinally, and unlike 
the current study, neither Gruber-Baldini et al. nor Rattinger et al. accounted for the 
severity of dementia symptoms.  
Mielke et al. (2012) employed an alternative way to calculate usage of 
antidementia medications. The persistency index was developed to show the amount of 
drug exposure, and in DPS 21.1% of participants with AD regularly used ChEIs (Mielke 
et al., 2012). In those analyses, persistency of antidementia use was a significant 
predictor of dementia progression, but with divergent effects by gender. It may be that an 
approach that considered duration of antidementia use may have been a useful analysis in 
the present study. A final limitation to this study is related to the homogeneous nature of 
the Cache County Study participants, with being 99% White. While this is representative 
of the population of older adults in the county in 1995, generalizability of current 
findings to populations with greater ethnic minority representation, particularly with 
respect to use of antidementia medications, may be limited. 
 This project examined total severity of NPS. An area of future research is to 
examine specific cluster scores of similar/correlated NPI symptoms. Research has found 
that within the CCSMA data approximately 60% of individuals with AD reported one 
NPS or more, and of those who reported experiencing an NPS, specific clusters of 
symptoms were found to exist including psychotic, affective, and other neuropsychiatric 
disturbance (Lyketsos et al., 2001). An examination of cluster scores could identify 
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specific symptoms affected by antidementia medications. As previously mentioned, 
Cumbo and Ligori (2014), found that the largest improvements in NPS were found in 
agitation and aggression for participants using memantine or rivastigmine (Cumbo & 
Ligori, 2014). In view of the significant burden associated with NPS, future research 
could explore risk factors for NPS. Steinberg et al. (2006) for example, found that gender, 
age, dementia severity, APOE E4 allele, dementia diagnosis, time of observation, and 
general medical health influenced NPS. An example of an association was that dementia 
severity increased the risk of hallucinations and agitation but decreased the risk of 
depression (Steinberg et al., 2006). An additional factor that may affect NPS is caregiving 
style and caregiver relationship closeness. Research has shown that different caregiving 
styles and level of caregiver/care-recipient closeness were associated with progression of 
AD, specifically cognitive decline (Norton et al., 2009, 2013). An examination of these 
factors and their effects on NPS would be of interest.  
 While there are numerous short-term studies (less than 1 year) and RCTs, the 
current longitudinal, observational study is one of few studies with follow-up data up to 
16 years. The current findings of the high correspondence of use of antidementia and 
psychotropic medications reveals information about patterns of use, suggesting the 
possibility that participants and their caregivers turn to their health care providers to seek 
treatment when experiencing more severe dementia or when NPS emerge. An area of 
future work would be to examine whether earlier initiation of antidementia medications 
may decrease or delay the onset of NPS. 
  
64 
 
CHAPTER 4 
 
CONCLUSIONS 
 
 
The purpose of this study was to evaluate how antidementia medications affect 
the occurrence and severity of NPS and the informal costs of care. The literature is 
unclear whether cognitive abilities, functional impairment, or NPS are the most 
significant factor in increasing the cost of dementia care, but there is evidence that all 
contribute to higher informal costs. Results found antidementia medication use was not 
associated with informal costs, but when restricting the sample to individuals with mild 
dementia at baseline, antidementia medications were associated with lower informal 
costs. While the literature has suggested that antidementia medications may potentially 
reduce NPS, the current study did not support these findings. In fact, the concurrent use 
of antidementia and psychotropic medications was common and that both were 
associated with worse NPS. These results suggest that use of one or both classes of these 
medications may reflect greater severity of dementia; dementia severity was a significant 
contributor to informal costs.  
 The literature is mixed with respect to the effects of antidementia mediations on 
NPS, with many studies differing in the type of antidementia medication studied, duration 
of study, control for psychotropic medication, and location of study (e.g., nursing homes, 
private residence). Additionally, this study found that dementia severity, place of 
residence, and psychotropic medications all predicted NPS over the course of the study. 
Last, the high comorbid use of psychotropic medications with antidementia medications 
suggest that future studies examine patterns of use and at minimum, control for the use of 
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psychotropic medications in statistical models.  
The present study examined persons with dementia for up to 16 years, with most 
individuals being followed from a few years of dementia onset up to their deaths. Most 
research on antidementia medications consists of RCTs, which may limit the 
generalizability due to strict eligibility criteria. Being an observational, population-based 
study likely makes the results more generalizable to other samples of community 
dwelling residents with dementia and provides valuable information of the nature of 
antidementia medication use and the costs of informal care over the entire course of 
dementia.  
  
66 
 
 
REFERENCES 
 
 
2014 Alzheimer’s facts and figures. (2014). Retrieved from http://www.alz.org/ 
alzheimers_disease_facts_and_figures.asp 
2015 Alzheimer’s facts and figures. (2015). Retrieved from https://www.alz.org/facts/ 
downloads/facts_figures_2015.pdf 
2016 Alzheimer’s facts and figures. (2016). Retrieved from http://www.alz.org/ 
documents_custom/2016-facts-and-figures.pdf 
Allegri, R. F., Sarasola, D., Serrano, C. M., Taragano, F. E., Arizaga, R. L., Butman, J., 
& Lon, L. (2006). Neuropsychiatric symptoms as a predictor of caregiver burden 
in Alzheimer’s disease. Neuropsychiatric Disease and Treatment, 2(1), 105-110.  
Alzheimer’s Disease International. (2009). World Alzheimer report 2009 executive 
summary. Retrieved from https://www.alz.co.uk/research/files/World 
AlzheimerReport-ExecutiveSummary.pdf 
Alzheimer’s Disease International. (2013). World Alzheimer report 2013 executive 
summary. Retrieved from https://www.alz.co.uk/research/WorldAlzheimer 
Report2013ExecutiveSummary.pdf 
Alzheimer’s Disease International. (2015). World Alzheimer report 2015 executive 
summary. Retrieved from https://www.alz.co.uk/sites/default/files/pdfs/world-
alzheimer-report-2015-executive-summary-english.pdf 
American Psychological Association. (1987). Diagnostic and statistical manual of mental 
disorders (3rd ed.). Washington, DC: Author. 
Anticholinergic Cognitve Burden Scale. (2012). Retrieved from 
http://www.agingbraincare.org/uploads/products/ACB_scale_-_legal_size.pdf 
Atri, A. (2011). Effective pharmacological management of Alzheimer’s disease. The 
American Journal of Managed Care, 17(13), S346-S355.  
Beeri, M., Werner, P., Davidson, M., & Noy, S. (2002). The cost of behavioral and 
psychological symptoms of dementia (BPSD) in community dwelling 
Alzheimer’s disease patients. International Journal of Geriatric Psychiatry, 17, 
403-408.  
  
67 
 
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., 
Norton, M. C., ... Khachaturian, A. (1999). APOE-E4 count predicts age when 
prevalence of AD increases, then declines. Neurology, 53, 321-331.  
Burns, A., Bernabei, R., Bullock, R., Cruz Jentoft, A., Frolich, L., Hock, C., ... Schwalen, 
S. (2009). Safety and efficacy of galantamine (reminyl) in severe Alzheimer’s 
disease (the SERAD study): A randomized, placebo-controlled, double-blind trial. 
Neurology, 8(39-47).  
Burns, A., Spiegel, R., & Quarg, P. (2004). Efficacy of rivastigmine in subjects with 
moderately severe Alzheimer’s disease. International Journal of Geriatric 
Psychiatry, 19, 243-249.  
Campbell, N. L., Boustani, M. A., Lane, K. A., Gao, S., Hendrie, H., Khan, B. A., ... 
Hall, K. (2010). Use of anticholinergics and the risk of cognitive impairment in an 
African American population. Neurology, 13(75), 152-159.  
Carriere, I., Fourrier-Reglat, A., Dartigues, J., Rouaud, O., Pasquier, F., Ritchie, K., & 
Ancelin, M. (2009). Drugs with anticholinergic properties, cognitive decline, and 
dementia in an elderly general population. Archives of Internal Medicine, 169, 
1317-1324.  
Clark, C. M., & Ewbank, D. C. (1996). Performance of the Dementia Severity Rating 
Scale: A caregiver questionnaire for rating severity in Alzheimer disease. 
Alzheimer’s Disease and Associated Disorders, 10(1), 31-39.  
Cumbo, E. (2005). Differential effects of rivastigmine, galantamine, and donepezil on 
behavioural and psychological symptoms in patients with Alzheimer’s disease: 
18-month, randomized, open-label trial. Primary Care and Community 
Psychiatry, 10(3), 95-102.  
Cumbo, E., & Ligori, L. D. (2014). Differential effects of current specific treatments on 
behavioral and psychological symptoms in patients with Alzheimer’s disease: A 
12-month, randomized, open-label trial. Journal of Alzheimers Disease, 39(3), 
477-485. doi:10.3233/JAD-131190 
Cummings, J. L. (1997). The Neuropsychiatric Inventory: Assessing psychopathology in 
dementia patients. Neurology, 48(5), S10-S16.  
Cummings, J. L., Mackell, J., & Kaufer, D. (2008). Behavioral effects of current 
Alzheimer’s disease treatments: a descriptive review. Alzheimer’s & Dementia, 
4(49-60).  
  
68 
 
Davis, K. L., Marin, D. B., Kane, R., Patrick, D., Peskind, E. R., Raskind, M. A., & 
Puder, K. L. (1997). The Caregiver Activity Survey (CAS): development and 
validation of a new measure for caregivers of persons with Alzheimer’s disease. 
International Journal of Geriatric Psychiatry, 12(10), 978-988.  
de Medeiros, K., Robert, P., Gauthier, S., Stella, F., Politis, A., Leoutsakos, J., ... 
Lyketsos, C. G. (2010). The Neuropsychiatric Inventory-Clinical rating scale 
(NPI-C): Reliability and validity of a revised assessment of neuropsychiatric 
symptoms in dementia. International Psychogeriatrics, 22(6), 984-994.  
Fillit, H., & Hill, J. (2004). The economic benefits of acetylcholinesterase inhibitors for 
patients with Alzheimer disease and associated dementias. Alzheimer’s Disease 
and Associated Disorders, 18(1), S24-S29.  
Fillit, H., & Hill, J. (2005). Economics of dementia and pharmacoeconomics. The 
American Journal of Geriatric Pharmacotherapy, 3(1), 39-48.  
Gillespie, P., O’Shea, E., Cullinan, J., Lacey, L., Gallagher, D., Ni Mhaolain, A., & 
Lawlor, B. (2013). The effects of dependence and function on costs of care for 
Alzheimer’s Disease and mild cognitive impairment in Ireland. International 
Journal of Geriatric Psychiatry, 28, 256-264.  
Grimmer, T., & Kurz, A. (2006). Effects of cholinesterase inhibitors on behavioral 
disturbances in Alzheimer’s disease. Drugs Aging, 23(12), 957-967.  
Grover, G., Sabharwal, A., & Mittal, J. (2013). An application of gamma generalized 
linear model for estimation of survival function of diabetic nephropathy patients. 
International Journal of Statistics in Medical Research, 2, 209-219.  
Gruber-Baldini, A. L., Stuart, B., Zuckerman, I. H., Simoni-Wastila, L., & Miller, R. 
(2007). Treatment of dementia in community-dwelling and institutionalized 
medicare beneficiaries. Journal of American Geriatric Society, 55(10), 1508-
1516. doi:10.1111/j.1532-5415.2007.01387.x 
Gustafsson, M., Sandman, P., Karlsson, S., Gustafson, Y., & Lovheim, H. (2013). 
Association between behavioral and psychological symptoms and psychotropic 
drug use among old people with cognitive impairment living in geriatric care 
settings. Psychogeriatrics, 25(9), 1415-1423.  
Hartz, S., Getsios, D., Tao, S., Blume, S., & Maclaine, G. (2012). Evaluating the cost 
effectiveness of donepezil in the treatment of Alzheimer’s disease in Germany 
using discrete event simulation. BMC Neurology, 12, 1-12.  
Hashimoto, M., Yatabe, Y., Kaneda, K., Honda, K., & Ikeda, M. (2009). Impact of 
donepezil hydrochloride on the care burden of family caregivers of patients with 
Alzheimer’s disease. Psychogeriatrics, 9, 196-203.  
69 
 
Hellweg, R., Wirth, Y., Janetzky, W., & Hartmann, S. (2012). Efficacy of memantine in 
delaying clinical worsening in Alzheimer’s disease (AD): Responder analyses of 
nine clinical tries with patients with moderate to severe AD. International Journal 
of Geriatric Psychiatry, 27, 651-656.  
Herrmann, N., Lanctôt, K., Sambrook, R., Lesnikova, N., Hébert, R., McCracken, P., … 
Nguyen, E. (2006). The contribution of neuropsychiatric symptoms to the cost of 
dementia care. International Journal of Geriatric Psychiatry, 21, 972-976.  
Hughes, C. P., Berg, L., Danzinger, W. L., Coben, L. A., & Martin, R. L. (1982). A new 
clinical scale for the staging of dementia. British Journal of Psychiatry, 55, 566-
572.  
Hurd, M., Martorell, P., Delavande, A., Mullen, K., & Langa, K. M. (2013). Monetary 
costs of dementia in the United States. The New England Journal of Medicine, 
368(4), 1326-1334.  
illar-Fernadez, I. I., Bjerrum, L. L., Feja, C. C., & Rabanaque, M. J. (2009). Variability in 
the prescription of cholinesterase inhibitors and memantine. Dementia and 
Geriatric Cognitive Disorders, 28(4), 373-379.  
Institute for Digital Research and Education. (2016). FAQ: How do I interpret a 
regression model when some variables are log transformed? Retrieved from 
http://www.ats.ucla.edu/stat/mult_pkg/faq/general/log_transformed_regression. 
htm 
Jorm, A. F., Scott, R., & Jacomb, P. A. (1989). Assessment of cognitive decline in 
dementia by informant questionnaire. International Journal of Geriatric 
Psychiatry, 4, 35-39.  
Langa, K. M., Chernew, M. E., Kabeto, M. U., Herzog, A. R., Ofstedal, M., Willis, R. J., 
... Rendrick, A. M. (2001). National estimates of the quantity and cost of informal 
caregiving for the elderly with dementia. Journal of General Internal Medicine, 
16, 770-778.  
Leicht, H., Heinrich, S., Heider, D., Bachmann, C., Bickel, H., van den Bussche, H., ... 
König, H. (2011). Net costs of dementia by disease stage. Acta Psychiatrica 
Scandinavica, 124, 384-395.  
Leicht, H., Konig, H., Stuhldreher, N., Bachmann, C., Bickel, H., Fuchs, A., ... Maier, W. 
(2013). Predictors of costs in dementia in a longitudinal perspective. PLOS One, 
8(7), 1-10.  
Leon, J., Cheng, C. K., & Neumann, P. J. (1998). Alzheimer’s disease care: Costs and 
potential savings. Health Affairs, 17(6), 206-216.  
70 
 
Lin, J., O’Connor, E., Rossom, R., Perdue, L., Burda, B., Thompson, M., & Eckstrom, E. 
(2013). Screening for cognitive impairment in older adults: An evidence update 
for the U.S. Preventive Services Task Force. Rockville (MD): Agency for 
Healthcare Research and Quality; (Evidence Syntheses, No. 107). Retrieved from 
http://www.ncbi.nlm.nih.gov/books/NBK174643/ 
Lyketsos, C. G., Galik, E., Steele, C., Steinberg, M., Rosenblatt, A., Warren, A., ... 
Brandt, J. (1999). The General Medical Health Rating: A bedside global rating of 
medical comorbidity in patients with dementia. Journal of the American 
Geriatrics Society, 47, 487-491.  
Lyketsos, C. G., Sheppard, J. M., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, 
D. C., & Breitner, J. (2001). Neuropsychiatric disturbance in Alzheimer’s disease 
clusters into three groups: the Cache County study. International Journal of 
Geriatric Psychiatry, 16, 1043-1053.  
Lyketsos, C. G., Toone, L., Tschanz, J. T., Rabins, P. V., Steinberg, M., Onyike, C. U., ... 
Welsh-Bohmer, K. A. (2005). Population-based study of medical comorbidity in 
early dementia and ‘cognitive impairment no dementia (CIND)’: Association with 
functional and cognitive impairment: The Cache County Study. The American 
Journal of Geriatric Psychiatry, 13(8), 656-664.  
Marin, D. B., Dugue, M., Schmeidler, J., Santoro, J., Neugroschi, J., Zaklad, G., ... Davis, 
K. L. (2000). The Caregiver Activity Survey (CAS): Longitudinal validation of an 
instrument that measure time spent caregiving for individuals with Alzheimer’s 
disease. International Journal of Geriatric Psychiatry, 15, 680-686.  
McKhann, G., Drachman, D., Folstein, M. F., Katzman, R., Price, D., & Stadlan, E. 
(1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-
ADRDA work group under the auspices of Department of Health and Human 
Services Task Force on Alzheimer’s Disease. Neurology, 34(7), 939-944.  
Mielke, M. M., Leoutsakos, J. M., Corcoran, C. D., Green, R. C., Norton, M. C., Welsh-
Bohmer, K. A., ... Lyketsos, C. G. (2012). Effects of Food and Drug 
Administration-approved medications for Alzheimer’s disease on clinical 
progression. Alzheimers Dementia, 8(3), 180-187. doi:10.1016/j.jalz.2011.02.011 
Moore, M. J., Zhu, C. W., & Clipp, E. C. (2001). Informal costs of dementia care: 
estimates from the national longitudinal caregiver study. Journal of Gerontology, 
56B(4), S219-S228.  
Murman, D. L., & Colenda, C. C. (2005). The economic impact of neuropsychiatric 
symptoms in Alzheimer’s disease. Parmacoeconomics, 23(3), 227-242.  
  
71 
 
Norton, M. C., Clark, C., Fauth, E. B., Piercy, K. W., Pfister, R., Green, R. C., ... 
Tschanz, J. T. (2013). Caregiver personality predicts rate of cognitive decline in a 
community sample of persons with Alzheimer’s disease. The Cache County 
Dementia Progression Study. International Psychogeriatrics, 25(10), 1629-1637. 
doi:10.1017/S1041610213001105 
Norton, M. C., Piercy, K. W., Rabins, P. V., Green, R. C., Breitner, J. C., Ostbye, T., ... 
Tschanz, J. T. (2009). Caregiver-recipient closeness and symptom progression in 
Alzheimer disease. The Cache County Dementia Progression Study. Journal of 
Gerontology, Series B: Psychological and Social Sciences, 64(5), 560-568. 
doi:10.1093/geronb/gbp052 
O'Bryant, S. E., Lacritz, L. H., Hall, J., Waring, S. C., Chan, W., Khodr, Z. G., ... Cullum, 
M. (2010). Validation of the New Interpretive Guidelines for the Clinical 
Dementia Rating Scale Sum of Boxes Score in the National Alzheimer’s 
Coordinating Center Database. Archives of Neurology, 67(6), 746-749.  
Okura, T., & Langa, K. M. (2011). Caregiver burden and neuropsychiatric symptoms in 
older adults with cognitive impairment: The aging, demographics, and memory 
study (ADAMS). Alzheimer’s Disease and Associated Disorders, 25(2), 116-121.  
Penrod, J. D., Kane, R. L., Finch, M. D., & Kane, R. A. (1998). Effects of post hospital 
Medicare home health and informal care on patient functional status. Health 
Services Research, 33, 513-529.  
Rapp, T., Andrieu, S., Molinier, L., Grand, A., Cantet, C., Mullins, D., & Vellas, B. 
(2012). Exploring the relationship between Alzheimer's disease severity and 
longitudinal costs. Value in Health, 15, 412-419.  
Rattinger, G. B., Burcu, M., Dutcher, S. K., Chhabra, P. T., Rosenberg, P. B., Simoni-
Wastila, L., ... Zuckerman, I. H. (2013). Pharmacotherapeutic management of 
dementia across settings of care. Journal of American Geriatric Society, 61(5), 
723-733. doi:10.1111/jgs.12210 
Rattinger, G. B., Fauth, E., Behrens, S., Sanders, C., Schwartz, S., Norton, M. C., ... 
Tschanz, J. T. (2016). Closer caregiver and care-recipient relationships predict 
lower informal costs of dementia care: The Cache County Dementia Progression 
Study. Alzheimer’s & Dementia, 12(8), 917-924.  
Rattinger, G. B., Schwartz, S., Mullins, C. D., Corcoran, C. D., Zuckerman, I. H., 
Sanders, C., ... Tschanz, J. T. (2015). Dementia severity and the longitudinal costs 
of informal care in the Cache County population. Alzheimer’s & Dementia, 11(8), 
946-954.  
Riikonen, M., Makela, K., & Perala, S. (2010). Safety and monitoring technologies for 
the homes of people with dementia. Gerontechnology, 9(1), 32-45.  
72 
 
Rive, B., Asrsland, D., Grishchenko, M., Cochran, J., Lamure, M., & Toumi, M. (2012). 
Cost-effectiveness of memantine in moderate and severe Alzheimer’s disease in 
Norway. International Journal of Geriatric Psychiatry, 27, 573-582.  
Rockwood, K., Strang, D., MacKnight, C., Downer, R., & Morris, J. C. (2000). Interrater 
reliability of the clinical dementia rating in a multicenter trial. Journal of the 
American Geriatrics Society, 48, 558-559.  
Rodda, J., Morgan, S., & Walker, Z. (2009). Are cholinesterase inhibitors effective in the 
management of the behavioral and psychological symptoms of dementia in 
Alzheimer’s disease? A systematic review of randomized, placebo-controlled 
trials of donepezil, rivastigmine and galantamine. International Psychogeriatrics, 
21(5), 813-824.  
Rosenberg, P. B., Mielke, M. M., Han, D., Leoutsakos, J. S., Lyketsos, C. G., Rabins, P. 
V., ... Tschanz, J. T. (2012). The association of psychotropic medication use with 
the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. 
International Journal of Geriatric Psychiatry, 27(12), 1248-1257. 
doi:10.1002/gps.3769 
Rountree, S. D., Atri, A., Lopez, O. L., & Doody, R. S. (2013). Effectiveness of 
antidementia drugs in delaying Alzheimer’s disease progression. Alzheimer’s & 
Dementia, 9, 338-345.  
Rymer, S., Salloway, S., Norton, L., Malloy, P., Correia, S., & Monast, D. (2002). 
Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer 
disease. Alzheimer’s Disease and Associated Disorders, 16(248-253).  
Schwarzkopf, L., Menn, P., Kunz, S., Holle, R., Lauternberg, J., Marx, P., … Grassel, E. 
(2011). Costs of care for dementia patients in community settings: An analysis for 
mild and moderate disease stage. Value in Health, 14, 827-835.  
Skidmore-Roth, L. (2009). 2009 Mosby’s nursing drug reference (22nd ed.). City, ST: 
Mosby Elsevier. 
Steinberg, M., Corcoran, C., Tschanz, J. T., Huber, C., Welsh-Bohmer, K., Norton, M. 
C., ... Lyketsos, C. G. (2006). Risk factors for neuropsychiatric symptoms in 
dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 
21(9), 824-830. doi:10.1002/gps.1567 
Stella, F., Laks, J., Govone, J. S., de Medeiros, K., & Forlenza, O. Z. (2016). Association 
of neuropsychiatric syndromes with global clinical deterioration in Alzheimer’s 
disease patients. International Psychogeriatric Association, 28(5), 779-786.  
  
73 
 
Taylor, D. H. J., Ostbye, T., Langa, K. M., Weir, D., & Plassman, B. L. (2009). The 
accuracy of Medicare claims as an epidemiological tool: the case of dementia 
revisited. Journal of Alzheimer’s Disease, 17, 807-815.  
Tschanz, J. T., Corcoran, C. D., Schwartz, S., Treiber, K., Green, R. C., Norton, M. C., ... 
Lyketsos, C. G. (2011). Progression of cognitive, functional, and neuropsychiatric 
symptoms in a population cohort with Alzheimer dementia: The Cache County 
Dementia Progression Study. The American Journal of Geriatric Psychiatry, 
19(6), 532-542.  
Tschanz, J. T., Welsh-Bohmer, K. A., Skoog, I., West, N., Norton, M. C., Wyse, B. W., 
... Breitner, J. C. S. (2000). Dementia diagnoses from clinical and 
neuropsychological data compared: The Cache County Study. Neurology, 54(6), 
1290-1296.  
U.S. Department of Labor. (2016). Occupational employment statistics. Washington, DC: 
Author. Retrieved from http://www.bls.gov/oes/tables.htm 
U.S. Department of Labor, Bureau of Labor Statistics. (2016). Consumer Price Index. 
Retrieved from http://www.bls.gov/cpi/home.htm 
Verbeke, G., & Molenberghs, G. (2000). Linear mixed models for longitudinal data. 
Secaucus, New Jersey: Springer. 
Wimo, A., Von Strauss, E., Nordberg, G., Sassi, F., & Johansson, L. (2002). Time spent 
on informal and formal care giving for persons with dementia in Sweden. Health 
Policy, 61, 255-268.  
Wolstenholme, J., Fenn, P., Gray, A., Keene, J., Jacoby, R., & Hope, T. (2002). 
Estimating the relationship between disease progression and cost of care in 
dementia. British Journal of Psychiatry, 181, 36-42.  
Zahodne, L. B., Ornstein, K., Cosentino, S., Devanand, D. P., & Stern, Y. (2015). 
Longitudinal relationships between Alzheimer disease progression and psychosis, 
depressed mood, and agitation/aggression. American Journal of Geriatric 
Psychiatry, 23(2), 130-140. doi:10.1016/j.jagp.2013.03.014 
Zandi, P. (2005). Do statins reduce risk of incident dementia and Alzheimer disease?: 
The Cache County Study. Archives of General Psychiatry, 62(2), 217-224.  
Zhu, C. W., Leibman, C., McLaughlin, T., Zbrozek, A. S., Scarmeas, N., & Albert, M. 
(2008). Patient dependence and longitudinal changes in costs of care in 
Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 26(5), 416-
423.  
  
74 
 
Zhu, C. W., Scarmeas, N., Torgan, R., Albert, M., Brandt, J., Blacker, D., ... Stern, Y. 
(2006a). Clinical characteristics and longitudinal changes of informal costs of 
Alzheimer’s disease in the community. Journal of American Geriatrics Society, 
54(10), 1596-1602.  
Zhu, C. W., Scarmeas, N., Torgan, R., Albert, M., Brandt, J., Blacker, D., ... Stern, Y. 
(2006b). Longitudinal study of effects of patient characteristics on direct costs in 
Alzheimer disease. Neurology, 67(6), 998-1005.
75 
 
APPENDICES 
  
76 
 
Appendix A 
 
Medication Record from the Cache County Study on Memory in Aging
77 
 
 
  
78 
 
 
  
79 
 
 
 
  
80 
 
 
  
81 
 
 
  
82 
 
 
83 
 
Appendix B 
 
Anticholinergic Cognitive Burden Scale
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Drugs with ACB Score of 1  
Generic Name Brand Name 
Alimemazine Theralen™ 
Alverine Spasmonal™ 
  
Alprazolam Xanax™ 
  
Aripiprazole Abilify™ 
Asenapine Saphris™ 
Atenolol Tenormin™ 
Bupropion Wellbutrin™, Zyban™ 
Captopril Capoten™ 
Cetirizine Zyrtec™ 
Chlorthalidone Diuril™, Hygroton™ 
Cimetidine Tagamet™ 
Clidinium Librax™ 
Clorazepate Tranxene™ 
Codeine Contin™ 
Colchicine Colcrys™ 
Desloratadine Clarinex™ 
Diazepam Valium™ 
Digoxin Lanoxin™ 
Dipyridamole Persantine™ 
Disopyramide Norpace™ 
Fentanyl Duragesic™, Actiq™ 
Furosemide Lasix™ 
Fluvoxamine Luvox™ 
Haloperidol Haldol™ 
Hydralazine Apresoline™ 
Hydrocortisone Cortef™, Cortaid™ 
Iloperidone Fanapt™ 
Isosorbide Isordil™, Ismo™ 
Levocetirizine Xyzal™ 
Loperamide Immodium™, others 
Loratadine Claritin™ 
Metoprolol Lopressor™, Toprol™ 
Morphine MS Contin™, Avinza™ 
Nifedipine Procardia™, Adalat™ 
Paliperidone Invega™ 
Prednisone Deltasone™, Sterapred™ 
Quinidine Quinaglute™ 
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Ranitidine Zantac™ 
Risperidone Risperdal™ 
Theophylline Theodur™, Uniphyl™ 
Trazodone Desyrel™ 
Triamterene Dyrenium™ 
Venlafaxine Effexor™ 
Warfarin Coumadin™  
 
 
Drugs with ACB Score of 2  
Generic Name Brand Name 
Amantadine Symmetrel™ 
Belladonna Multiple 
Carbamazepine Tegretol™ 
Cyclobenzaprine Flexeril™ 
Cyproheptadine Periactin™ 
Loxapine Loxitane™ 
Meperidine Demerol™ 
Methotrimeprazine Levoprome™ 
  
Molindone Moban™ 
Nefopam Nefogesic™ 
Oxcarbazepine Trileptal™ 
Pimozide Orap™ 
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Drugs with ACB Score of 3  
Generic Name Brand Name 
Amitriptyline Elavil™ 
Amoxapine Asendin™ 
Atropine Sal-Tropine™ 
Benztropine Cogentin™ 
Brompheniramine Dimetapp™ 
Carbinoxamine Histex™, Carbihist™ 
Chlorpheniramine Chlor-Trimeton™ 
Chlorpromazine Thorazine™ 
Clemastine Tavist™ 
Clomipramine Anafranil™ 
Clozapine Clozaril™ 
Darifenacin Enablex™ 
Desipramine Norpramin™ 
Dicyclomine Bentyl™ 
Dimenhydrinate Dramamine™, others 
Diphenhydramine Benadryl™, others 
Doxepin Sinequan™ 
Doxylamine Unisom™, others 
Fesoterodine Toviaz™ 
Flavoxate Urispas™ 
Hydroxyzine Atarax™, Vistaril™ 
Hyoscyamine Anaspaz™, Levsin™ 
Imipramine Tofranil™ 
Meclizine Antivert™ 
Methocarbamol Robaxin™ 
Nortriptyline Pamelor™ 
Olanzapine Zyprexa™ 
Orphenadrine Norflex™ 
Oxybutynin Ditropan™ 
Paroxetine Paxil™ 
Perphenazine Trilafon™ 
Promethazine Phenergan™ 
Propantheline Pro-Banthine™ 
Propiverine Detrunorm™ 
Quetiapine Seroquel™ 
Scopolamine Transderm Scop™ 
Solifenacin Vesicare™ 
Thioridazine Mellaril™ 
Tolterodine Detrol™ 
Trifluoperazine Stelazine™ 
Trihexyphenidyl Artane™ 
Trimipramine Surmontil™ 
Trospium Sanctura™ 
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Appendix C 
 
 General Medical Health Rating (GMHR)
88 
 
SECTION V: GMHR RATING SUBJECT 
 
RESIDENCE 
1 HOME/OUTPATIENT 
2 RESIDENTIAL/ASSISTED LIVING-UNLOCKED UNITS 
2.1 ASSISTED LIVING-LOCKED UNITS 
3 SKILLED NURSING FACILITY  
Circle one of the numbers between 1 and 4 using the instructions next to each 
number. Please begin at the top and decide if the person meets each rating in 
sequence as written. If you are having trouble deciding between two adjacent ratings, 
rate the lower number.  
4 EXCELLENT 
no current unstable physical illness, may have 1-2 stable 
physical illnesses, is on very few medications, and appears 
healthy and in good physical condition 
3 GOOD 
may have one unstable physical illness that is being treated 
or a few controlled physical illnesses, is on few medications, 
and appears no more than mildly ill 
2 FAIR 
more than one unstable physical illness and/or numerous 
chronic medical conditions, several medications, appears 
moderately ill 
1 POOR 
several unstable physical illnesses, several medications, 
appears quite ill, probably in need of hospitalization or 
terminal/hospital care 
Other 
89 
 
Appendix D 
 
Neuropsychiatric Inventory (NPI)
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SECTION M: NPI DATA 
MA. Delusions  
In the last month, has (NAME) had beliefs that you know are not true? For example, 
insisting that people are trying to harm (HIM/HER) or steal from (HIM/HER). Has 
(HE/SHE) said that family members are not who they say they are or that the house is not 
(HIS/HER) home? I’m not asking about mere suspiciousness; I am interested if (NAME) 
is convinced that these things are happening to (HIM/HER).  
 
 YES NO  IV RF DK NA 
MAA.
  
Since (the last time mos/yrs) we saw 
(NAME) not including the last month has 
(he/she) had any of these beliefs? 
1 0 6 7 8 9 
#1 CHECKPOINT  IF YES RECORD ONSET 
DATE AND DATE 
STOPPED THEN GO TO 
MA1. IF NO GO TO MA14. 
ONSET DATE 
 
DATE STOPPED 
 
  /     
  /     
 
MB. Hallucinations  
 
In the last month, did (NAME) have hallucinations such as false visions or voices? Does 
(HE/SHE) seem to see, hear or experience things that are not present? By this question 
we do not mean just mistaken beliefs such as stating that someone who has died is still 
alive; rather we are asking if (NAME) actually has abnormal experiences of sounds or 
visions. 
 
 YES NO  IV RF DK NA 
MBB. Since (the last time mos/yrs) we saw 
(NAME) not including the last month has 
(he/she) had any of these experiences? 
1 0 6 7 8 9 
#3 CHECKPOINT  IF YES RECORD ONSET 
DATE AND DATE STOPPED 
THEN GO TO MB1. IF NO 
GO TO MB12. 
ONSET DATE 
 
DATE STOPPED 
 
  /     
  /     
YES (Go DATE OF 
ONSET)
 ...................................... 
1 
NO (GO TO MAA) ... 0 
NA (GO TO MAA) .... 9 
 
YES (Go DATE OF ONSET) 1 NO (GO TO MBB) .. 0 
NA (GO TO MBB) ... 9 
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Appendix E 
 
Caregiver Activity Survey (CAS)
99 
 
 
SECTION C: CAREGIVER ACTIVITY SURVEY (CAS) 
C1. Communicating with (NAME) 4. Looking after one’s appearance 
 Thinking back over the past day, 
how much time did you and others 
spend in the last 24 hours (day and 
night) doing these types of 
activities: 
 answering the same question 
again and again 
 trying to make sense of what 
the person says 
 leaving reminders for the 
person 
                                       
hours            minutes 
 Thinking back over the past day, 
how much time did you and others 
spend in the last 24 hours (day and 
night) doing these types of 
activities? 
 reminding the person to 
brush their teeth, brush their 
hair, apply cosmetics, shave 
or care for nails 
 helping the person to groom 
 setting out items for 
grooming activities 
 supervising grooming 
activities 
                                            
hours             minutes 
 
2. Dressing 5. Supervising the person 
 Thinking back over the past day, 
how much time did you and others 
spend in the last 24 hours (day and 
night) doing these types of 
activities; 
 reminding the person to 
dress 
 choosing what to wear 
 laying out clothes 
 helping the person to dress 
or undress 
 supervising the person 
dressing 
 keeping the person from 
undressing at the wrong time 
                                          
hours             minutes 
 Thinking back over the past day, 
how much time did you and others 
spend in the last 24 hours (day and 
night) doing these activities? 
 keeping an eye on the person 
to be sure that they do not 
wander off or get into some 
kind of difficulty 
 looking out for the person 
 preventing the person from 
getting lost 
 finding the person if they get 
lost 
                                            
hours               minutes 
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3. Eating C7.
 Thinking back over the past day, 
how much time did you and others 
spend in the last 24 hours (day and 
night) doing these type of activities: 
 reminding the person to eat 
 setting up utensils and food 
 cutting or arranging food on 
the plate 
 supervising or encouraging 
the person to eat 
 cleaning the person after 
eating 
                                                       
hours              minutes 
 
 
 
 
Completed By____________________ Certification License ________________ 
 
     Staff Position_______________________ 
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Appendix F 
 
Neuropsychiatric Inventory Score by Visit
102 
 
Figure F1. Neuropsychiatric Inventory Score visit 0. 
 
 
 
Figure F2. Neuropsychiatric Inventory Score Visit 1. 
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Figure F3. Neuropsychiatric Inventory Score Visit 2. 
 
 
Figure F4. Neuropsychiatric Inventory Score Visit 3. 
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Figure F5. Neuropsychiatric Inventory Score Visit 4.  
 
 
Figure F6. Neuropsychiatric Inventory Score Visit 5. 
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Figure F7. Neuropsychiatric Inventory Score Visit 6. 
 
Figure F8. Neuropsychiatric Inventory Score Visit 7. 
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Figure F9. Neuropsychiatric Inventory Score Visit 8. 
 
 
Figure F10. Neuropsychiatric Inventory Score Visit 9. 
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Figure F11. Neuropsychiatric Inventory Score Visit 10. 
 
 
Figure F12. Neuropsychiatric Inventory Score Visit 11. 
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Figure F13. Neuropsychiatric Inventory Score Visit 12. 
 
 
Figure F14. Neuropsychiatric Inventory Score Visit 13. 
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Figure F15. Neuropsychiatric Inventory Score Visit 14. 
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Appendix G 
 
Natural Log Transformation of Neuropsychiatric Inventory  
 
Score by Each Visit
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Figure G1. Natural log of the Neuropsychiatric Inventory score visit 0. 
 
 
Figure G2. Natural log of the Neuropsychiatric Inventory score visit 1. 
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Figure G3. Natural log of the Neuropsychiatric Inventory score visit 2. 
 
Figure G4. Natural log of the Neuropsychiatric Inventory score visit 3.  
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Figure G5. Natural log of the Neuropsychiatric Inventory score visit 4. 
 
Figure G6. Natural log of the Neuropsychiatric Inventory score visit 5. 
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Figure G7. Natural log of the Neuropsychiatric Inventory score visit 6. 
 
Figure G8. Natural log of the Neuropsychiatric Inventory score visit 7.  
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Figure G9. Natural log of the Neuropsychiatric Inventory score visit 8. 
 
 
Figure G10. Natural log of the Neuropsychiatric Inventory score visit 9. 
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Figure G11. Natural log of the Neuropsychiatric Inventory score visit 10. 
 
 
Figure G12. Natural log of the Neuropsychiatric Inventory score visit 11. 
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Figure G13. Natural log of the Neuropsychiatric Inventory score visit 12. 
 
 
Figure G14. Natural log of the Neuropsychiatric Inventory score visit 13. 
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 Figure G15. Natural log of the Neuropsychiatric Inventory score visit 14. 
 
  
Figure G16. Natural log of the Neuropsychiatric Inventory score visit 15. 
